Record
stringlengths 1
197k
|
|---|
<|newrecord|> nctId: NCT06260995 id: Ref: 230603 briefTitle: The Role of Intermediaries in Connecting Individuals to Local Physical Activity - Study Protocol overallStatus: RECRUITING date: 2023-09-01 date: 2024-05-31 date: 2024-06-30 date: 2024-02-15 date: 2024-02-21 name: University of Dublin, Trinity College class: OTHER briefSummary: Intermediaries help people to connect to community-based services and supports, including physical activity and exercise groups (physical activities). They do this by acting as a link person. After receiving a referral or self-referral, they conduct an assessment, connect people to services in the community, and follow-up with people over time.
|
This project will investigate if connecting to physical activities through an intermediary can improve health and wellbeing. It will also investigate people's experiences of working with an intermediary. This project is a pilot feasibility study, which means the investigators are evaluating the measures used and the way the trial is designed to see if they are suitable for a larger study in the future. conditions: Physical Inactivity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Social Prescribing Link Worker Intermediary Intervention name: Local Sports Partnership Community Development Officer Intervention measure: International Physical Activity Questionnaire - Short Form measure: Self-Efficacy for Exercise Scale measure: Short Warwick Edinburgh Mental Well-being Scale measure: Demographics and Health Status measure: Semi-structured Interviews - Intervention Participants measure: Overall Acceptability of the Intervention measure: Gatekeeper Recruitment Logs measure: Semi-structured Interviews - Gatekeepers sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Dublin, Trinity College Dublin status: RECRUITING city: Dublin 8 zip: D08 W9RT country: Ireland name: Megan O'Grady role: CONTACT phone: 018963613 email: [email protected] lat: 53.33306 lon: -6.24889 hasResults: False
|
<|newrecord|> nctId: NCT06260982 id: 2021PI148 briefTitle: Cognitive Disorders in Hereditary Spastic Paraplegia Type 4 acronym: SPG-TEP overallStatus: RECRUITING date: 2022-01-01 date: 2025-01 date: 2025-01-02 date: 2024-02-15 date: 2024-02-15 name: Central Hospital, Nancy, France class: OTHER briefSummary: Hereditary spastic paraplegia type 4 is the most frequent mutation of hereditary spastic paraplegias. It is commonly described as pure, with progressive weakness of the lower limbs, pyramidal syndrome and vesico-sphincter disorders. However, cognitive disorders have been reported for over 20 years, but remain poorly characterized. conditions: Spastic Paraplegia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: 18-FDG-PET measure: cognitive testing measure: Correlations between neuropsychological tests, clinical examination, PET and general data. measure: Genotype/Phenotype correlations sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Centre hospitalier régional universitaire status: RECRUITING city: Nancy zip: 54000 country: France name: Mathilde Renaud, MD, PhD role: CONTACT email: [email protected] lat: 48.68439 lon: 6.18496 hasResults: False
|
<|newrecord|> nctId: NCT06260969 id: TJHH-2023-WM13 briefTitle: Endovascular Treatment of Acute Ischemic Stroke With Underlying Intracranial Artery Stenosis overallStatus: RECRUITING date: 2022-09-01 date: 2025-09-30 date: 2025-09-30 date: 2024-02-15 date: 2024-02-15 name: Tianjin Huanhu Hospital class: OTHER briefSummary: The study is a prospective multicentre registry study. Patients admitted to 10 stroke centres nationwide from September 2022 to September 2025 with acute ischaemic stroke due to large vessel occlusion considering underlying ICAS and treated with emergency endovascular thrombolysis were included for analysis. Patients who met the general inclusion criteria underwent thrombectomy and the necessary remedial treatment. conditions: Large Vessel Occlusion conditions: Intracranial Artery Occlusion With Cerebral Infarction conditions: Endovascular Treatments conditions: Acute Ischemic Stroke studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 470 type: ESTIMATED name: balloon dilatation measure: Proportion of patients achieving a clinical prognosis of mRS 0-2 at 90 days measure: Proportion of patients with a good prognosis early after treatment measure: Change in final cerebral infarct volume relative to baseline at 24 (-2/+12) hours postoperatively on CT/MR measure: Vascular recanalization sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Huanhu Hospital status: RECRUITING city: Tianjin state: Tianjin country: China name: Ming Wei role: CONTACT phone: 13502182903 email: [email protected] lat: 39.14222 lon: 117.17667 hasResults: False
|
<|newrecord|> nctId: NCT06260956 id: U01-ROC-001 id: 1U01AI173032 type: NIH link: https://reporter.nih.gov/quickSearch/1U01AI173032 briefTitle: Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg acronym: ESCAPE overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-09 date: 2029-09 date: 2024-02-15 date: 2024-02-15 name: University of Rochester class: OTHER name: National Institute of Allergy and Infectious Diseases (NIAID) briefSummary: Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding. conditions: Allergy and Immunology conditions: Peanut and Nut Allergy conditions: Egg Allergy conditions: Food Allergy in Infants conditions: Food Allergy Peanut studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: National, parallel, two arm (one-to-one allocation), single blinded, randomized controlled trial. primaryPurpose: PREVENTION masking: TRIPLE maskingDescription: Due to the nature of the intervention, the subjects must know which arm they are assigned to, however, biostatistician and investigators will be blinded to study assignment. whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 400 type: ESTIMATED name: Avoidance name: Consumption measure: Egg sensitization measure: Peanut and egg specific IgG and IgG4 measure: Antibodies in maternal blood measure: Egg allergy measure: Antigen concentrations measure: Exploratory: Peanut sensitization measure: Exploratory: Symptoms measure: Exploratory: Peanut sensitization sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: University of Rochester city: Rochester state: New York zip: 14642 country: United States lat: 43.15478 lon: -77.61556 hasResults: False
|
<|newrecord|> nctId: NCT06260943 id: 20221220 id: NCI-2024-00566 type: REGISTRY domain: NCI Clinical Trials Reporting Program (CTRP) briefTitle: Targeted Navigation in Hepatocellular Carcinoma (HCC) overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2026-10-31 date: 2026-10-31 date: 2024-02-15 date: 2024-02-15 name: University of Miami class: OTHER name: The V Foundation briefSummary: The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients. The investigators would like to know whether there are needs that patients have or are aware of, especially those needs that the investigators have not been able to address. The investigators aim to develop a program that helps participants and participant's families to navigate the process of being diagnosed with liver cancer and receiving treatment. conditions: Hepatocellular Carcinoma conditions: Cholangiocarcinoma conditions: Hepatobiliary Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 50 type: ESTIMATED name: Target Navigation Pilot Program measure: Number of Days to First Contact measure: Number of Hours for Each Contact measure: Number of Days to First Appointment measure: Number of Days to First Treatment measure: Number of Months of Total Navigation measure: Number of Participants that Die Within One Year measure: Proportion of Participants Enrolled in Clinical Research sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Miami city: Miami state: Florida zip: 33136 country: United States name: Gloria Figueroa role: CONTACT phone: 305-243-0779 email: [email protected] name: Patricia Jones, MD role: CONTACT phone: (305) 243-0779 email: [email protected] name: Patricia Jones, MD role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 hasResults: False
|
<|newrecord|> nctId: NCT06260930 id: Value of chest ultrasonography briefTitle: Value of Chest Ultrasonography in ILD Screening overallStatus: COMPLETED date: 2017-01 date: 2019-09 date: 2019-12 date: 2024-02-15 date: 2024-02-15 name: Aswan University class: OTHER briefSummary: The main aim of this study is to detect the value of transthoracic ultrasonography in the diagnosis and assessment of ILDs in correlation to chest X- ray, blood gases, pulmonary function test and echocardiography and to compare it with high resolution CT (HRCT) as a golden diagnostic investigation. conditions: Interstitial Lung Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 80 type: ACTUAL measure: Sensitivity and specificity of the lung sonography for interstitial lung disease screening sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06260917 id: E2-23-4148 briefTitle: The Effect of Urinating Through the Zipper or by Pulling Down the Trousers on Uroflowmetry Parameters in LUTS overallStatus: COMPLETED date: 2023-11-01 date: 2023-12-31 date: 2023-12-31 date: 2024-02-15 date: 2024-02-15 name: Ankara City Hospital Bilkent class: OTHER briefSummary: There are many factors that affect uroflowmetry parameters. One of these is the urination position. Research has mostly focused on standing and sitting urination positions. However, those who prefer the standing position as a habit can urinate by opening the zipper or lowering the trousers. Although the effect of these two applications on uroflowmetry parameters in healthy men has been investigated in only one study, their effect on patients with lower urinary tract symptoms has not been examined. conditions: Benign Prostatic Hyperplasia conditions: Micturition Disorder conditions: Urinary Obstruction conditions: Urinary Tract Disease conditions: Urologic Diseases studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 80 type: ACTUAL name: position of urination measure: Qmax measure: PVR measure: Qave measure: Duration of voiding sex: MALE minimumAge: 45 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Bilkent City Hospital city: Ankara country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
|
<|newrecord|> nctId: NCT06260904 id: AIIMS BBSR/PGThesis/23-24/112 briefTitle: Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus overallStatus: NOT_YET_RECRUITING date: 2024-02-26 date: 2025-01-31 date: 2025-05-31 date: 2024-02-15 date: 2024-02-15 name: All India Institute of Medical Sciences, Bhubaneswar class: OTHER briefSummary: Lichen planus is an inflammatory disorder of unknown aetiology affecting the stratified squamous epithelia, with an estimated global prevalence of 0.22 to 0.5 %. Oral mucosa (Oral Lichen Planus; OLP) is the most commonly affected region. Corticosteroids are the primary treatment of choice. A prolonged treatment with steroids is required for clinical improvement, which increases the chances of long-term adverse effects. So, there is a need for newer, effective treatment modalities, such as retinoids, methotrexate, Janus kinase inhibitors, PDE4 inhibitors, etc.
|
Of these, methotrexate is a dihydrofolate reductase inhibitor that inhibits the replication and function of T and B lymphocytes. It has shown a good response to OLP (around 83%) in a study by Lajevardi et al. and can be considered a treatment option in patients with moderate to severe OLP. Apremilast is a drug with a novel immunomodulatory mechanism of action. It inhibits phosphodiesterase type IV, which increases levels of cyclic adenosine monophosphate (cAMP), thus activating protein kinase A and inhibiting various inflammatory mediators. Based on a pilot study by Paul et al., apremilast is associated with clinical improvement in lichen planus.
|
Among the various treatment options, there is a lack of head-on trials. Methotrexate is an immunosuppressant with various systemic adverse effects and requires close monitoring. Whereas apremilast is a non-immunosuppressive drug with a better safety profile, it does not show such adverse effects. These drugs can be used as an add-on to low-dose steroids in view of reducing the adverse effects associated with steroid therapy. To the best of our knowledge, there is no randomized controlled trial comparing these two drugs to date. Hence, the present study has been planned to evaluate the safety and efficacy of methotrexate versus apremilast as an add-on to the standard steroid therapy in OLP patients. conditions: Oral Lichen Planus studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized, add-on, active-controlled, open-label, parallel-design clinical trial primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: Prednisolone name: Apremilast name: Methotrexate measure: Pain by Visual Analogue Scale (VAS) score measure: Severity by Physician global assessment of disease (PGA) score measure: Severity and pain by oral mucosal disease severity score measure: serum IL 6 level measure: Quality of life by using oral health-related quality of life score (ORAL HEALTH IMPACT PROFILE - 14 ) measure: Incidence of treatment-emergent adverse events of both test and control group sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AIIMS Bhubaneswar city: Bhubaneswar state: Odisha zip: 751019 country: India name: Monalisa Jena, MD role: CONTACT phone: 09438884193 email: [email protected] name: Biswanath Behera, MD role: CONTACT phone: 07978351200 email: [email protected] name: Biswanath Behera role: SUB_INVESTIGATOR name: Madhusmita Sethy role: PRINCIPAL_INVESTIGATOR name: Mowdharani PS role: PRINCIPAL_INVESTIGATOR lat: 20.27241 lon: 85.83385 hasResults: False
|
<|newrecord|> nctId: NCT06260891 id: ZnSCD briefTitle: Zinc Supplementation in Sickle Cell Disease acronym: ZnSCD overallStatus: NOT_YET_RECRUITING date: 2025-04-01 date: 2026-09-30 date: 2026-09-30 date: 2024-02-15 date: 2024-03-13 name: University of California, San Francisco class: OTHER name: American Society Hematology, Research Collaborative name: Children's Hospital of Philadelphia name: Johns Hopkins University name: Baylor College of Medicine name: Children's National Research Institute name: Children's Hospital Medical Center, Cincinnati name: Newark Beth Israel Medical Center name: University of Pennsylvania briefSummary: The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-35 years old. The main question it aims to answer is: Which biomarkers are most responsive to zinc supplementation, and what is the maximum tolerated zinc dose that induces the desired changes in biomarkers of bone turnover? Participants will be recruited from 7 American Society Hematology Research Collaborative SCD Centers. Eligible SCD subjects will be invited to participate in the 16-week study, involving 2 baseline blood draws 4 weeks apart, followed by a 12-week zinc intervention. The findings from this study will be used to determine the dosage of zinc to be used in a larger, future study on the long term impact of zinc supplementation on bone health in SCD-SS. conditions: Sickle Cell Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a delayed start parallel design where all subjects will have a usual care period, 2 baseline samples 4 weeks apart, followed by a 12 week zinc intervention, with samples at 8 and 12 weeks. primaryPurpose: OTHER masking: QUADRUPLE maskingDescription: n/a the 2 zinc capsule dosages (25 and 40 mg) will be compounded to look identical whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 34 type: ESTIMATED name: 25 mg/day zinc name: 40 mg/day zinc measure: Biomarker of Bone Formation (PINP) measure: Biomarker of Bone Resorption (CTx) measure: Biomarker of Bone Formation (BSAP) measure: Biomarker of Bone Resorption (TRAP 5b) sex: ALL minimumAge: 15 Years maximumAge: 35 Years stdAges: CHILD stdAges: ADULT facility: UCSF Benioff Children's Hospital Oakland city: Oakland state: California zip: 94609 country: United States name: Ellen Fung, PhD role: CONTACT phone: 510-428-3885 phoneExt: 4939 email: [email protected] name: Beth Anne Martin role: CONTACT email: [email protected] lat: 37.80437 lon: -122.2708 hasResults: False
|
<|newrecord|> nctId: NCT06260878 id: REB23-0625 briefTitle: Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis acronym: STRIPE overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2027-12-31 date: 2028-06-30 date: 2024-02-15 date: 2024-02-15 name: University of Calgary class: OTHER briefSummary: This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). PEP is the most common serious ERCP-related adverse event (AE), occurring in 5-15% of patients, and associated with significant morbidity, mortality, and healthcare utilization. Given the current lack of data on effectiveness of short-term fluid regimens in PEP prevention to inform practice, the results of the proposed study have the strong potential to impact ERCP practices worldwide, whether positive or negative. conditions: Post-ERCP Acute Pancreatitis studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 505 type: ESTIMATED name: Intravenous Ringer's lactate measure: Serum amylase measure: Pancreatitis measure: Bleeding measure: Cholangitis measure: Cardiorespiratory adverse event measure: Serum lipase measure: Electrolytes measure: Creatinine measure: Brain natriuretic peptide sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06260865 id: E-ETH-01K-CI02 briefTitle: A Confirmatory Trial of Multidisciplinary Digital Therapeutics for Patellofemoral Pain Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2024-07-31 date: 2024-08-30 date: 2024-02-15 date: 2024-02-15 name: EverEx Inc. class: INDUSTRY briefSummary: This randomized controlled confirmatory study will be evaluating an mobile application, MORA Cure (ETH-01K), owned by EverEx, Inc., to examine safety and effectiveness in individuals with patellofemoral pain syndrome. conditions: Patellofemoral Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multicenter randomized controlled trial primaryPurpose: TREATMENT masking: NONE count: 216 type: ESTIMATED name: MORA Cure name: Treatment as Usual measure: Usual pain severity assessed by the Visual Analogue Scale (VAS) measure: Usual pain severity assessed by the Visual Analogue Scale (VAS) measure: Worst pain severity assessed by the Visual Analogue Scale (VAS) measure: Functional disability assessed by the Kujala Patellofemoral Scale measure: Health-related quality of life assessed by EuroQol five-dimensional (EQ-5D) measure: Assessment of mental health symptoms specific to depression as assessed by the Patient Health Questionnaire-9 (PHQ-9) measure: Assessment of catastrophic thinking measured by Pain Catastrophizing Scale (PCS) measure: Flexion and extension strength of knee measure: Treatment adherence sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Myongji Hospital city: Goyang-si state: Gyeonggi-do zip: 10475 country: Korea, Republic of lat: 37.65639 lon: 126.835 facility: Hanyang University Guri Hospital city: Guri-si state: Gyeonggi-do zip: 11923 country: Korea, Republic of lat: 37.5986 lon: 127.1394 facility: CHA Bundang Medical Center city: Seongnam-si state: Gyeonggi-do zip: 13496 country: Korea, Republic of lat: 37.43861 lon: 127.13778 facility: Inha University Hospital city: Junggu state: Incheon-si zip: 22332 country: Korea, Republic of lat: 37.69175 lon: 126.60024 facility: Chung-Ang University Hospital city: Dongjak state: Seoul zip: 06973 country: Korea, Republic of lat: 35.15713 lon: 126.8166 facility: Seoul Metropolitan Government-Seoul National University Boramae Medical Center city: Dongjak state: Seoul zip: 07061 country: Korea, Republic of lat: 35.15713 lon: 126.8166 facility: Kyung Hee University Hospital at Gangdong city: Gangdong state: Seoul zip: 05278 country: Korea, Republic of facility: The Catholic University of Korea Seoul St. Mary's Hospital city: Seocho state: Seoul zip: 06591 country: Korea, Republic of lat: 37.49056 lon: 127.02 facility: Seoul National University Bundang Hospital city: Gyeonggi-do zip: 13620 country: Korea, Republic of lat: 37.58944 lon: 126.76917 facility: Asan Medical Center city: Seoul zip: 05505 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
|
<|newrecord|> nctId: NCT06260852 id: ES20/Th8/23-11-2023 briefTitle: Identification of Minimum Focal Points in Vision Curve Formation overallStatus: RECRUITING date: 2024-02-01 date: 2024-08 date: 2024-08 date: 2024-02-15 date: 2024-03-07 name: Democritus University of Thrace class: OTHER briefSummary: The primary objective of this study is to identify how many focal points and at which distances are necessary for reliable visual curve formation and area of the curve (AoC) calculation using mathematical models and comparing the results to measurements acquired from participants that underwent uncomplicated pseudophakic presbyopia surgery. conditions: Presbyopia conditions: Pseudophakia conditions: Cataract conditions: Refractive Errors studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Diagnostic Test: Visual Acuity Assessment measure: Visual curves interpolation measure: Area of the curve (AOC) assessment measure: Visual acuity assessment sex: ALL minimumAge: 40 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Ophthalmology, University Hospital of Alexandroupolis status: RECRUITING city: Alexandroupolis state: Evros zip: 68100 country: Greece name: Georgios Labiris, MD, PhD role: CONTACT phone: 00302551030405 email: [email protected] lat: 40.84995 lon: 25.87644 hasResults: False
|
<|newrecord|> nctId: NCT06260839 id: KY20232442-F-1 briefTitle: the Effect of Minimally Invasive Technique Assisted by Magnetic Resonance Neurography overallStatus: RECRUITING date: 2024-02-16 date: 2024-12-01 date: 2024-12-31 date: 2024-02-15 date: 2024-02-26 name: He Xiang class: OTHER briefSummary: The goal of this clinical trial is to to compare the therapeutic effect of minimally invasive surgery guided by magnetic resonance neurography(MRN) compared with non-magnetic resonance assisted minimally invasive surgery in patients with moderate to severe gluteal muscle contracture(GMC). The main question it aims to answer are: magnetic resonance neurography can better help optimize the surgical path of minimally invasive surgery in the treatment of gluteal muscle contracture.
|
Participants will underwent preoperative magnetic resonance examination according to different groups, and then the experimental group designed individualized surgical approach and MRN-assisted minimally invasive release according to the imaging findings. In the control group, preoperative magnetic resonance examination was only used to assist in the diagnosis and evaluation of gluteal muscle contracture, and the magnetic resonance results were not used to assist in the design of surgical approach. In the control group, non-MRN-assisted minimally invasive release was performed. The researchers will compare the intraoperative surgery-related indicators and postoperative hip function scores and complications of patients in different groups to see if magnetic resonance-assisted surgery has a better postoperative effect. conditions: Orthopedic Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 44 type: ESTIMATED name: magnetic resonance neurography name: no magnetic resonance neurography measure: Hip joint outcome score(HOS) scale measure: Objective hip function scoring scale measure: Hip joint function of patients measure: Imaging data of patients with gluteal muscle contracture measure: Record the duration of the patient 's surgery measure: The record of the length of the surgical incision of the patient measure: Measurement of intraoperative blood loss measure: The first ambulation time after operation measure: postoperative pain score measure: Postoperative patients were satisfied with the appearance measure: The record of postoperative wound infection measure: The occurrence of postoperative wound fat liquefaction measure: Postoperative wound peripheral nerve vascular injury measure: Postoperative incision hematoma formation measure: Gluteal muscle contracture severity ZHAO 's classification measure: Demographic characteristics of patients sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xijing Hospital, the Fourth Military Medical University status: RECRUITING city: Xian state: Shaanxi zip: 710032 country: China name: Xiang He, MS role: CONTACT phone: 8684771013 email: [email protected] name: Long Bi, Prof. role: CONTACT phone: 8684771013 email: [email protected] name: Long Bi, Prof. role: PRINCIPAL_INVESTIGATOR lat: 34.25833 lon: 108.92861 hasResults: False
|
<|newrecord|> nctId: NCT06260826 id: 3977/QĐ-HVQY briefTitle: CPAP on Oxygenation and Pulmonary Function in Elderly Patients After Major Open Abdominal Surgery acronym: CPAP overallStatus: COMPLETED date: 2021-12-01 date: 2022-08-20 date: 2022-08-30 date: 2024-02-15 date: 2024-02-15 name: Nguyen Dang Thu class: OTHER briefSummary: Postoperative continuous positive airway pressure (CPAP) can improve lung function. The risk of pulmonary complications is high after major abdominal surgery but may be reduced by prophylactic postoperative noninvasive ventilation using CPAP. This study compared the effects of auto-CPAP via a nasal mask (JPAP) and constant-CPAP via a facial mask (O2-Max Trio) on oxygenation and pulmonary function in elderly patients after major open abdominal surgery. conditions: Continuous Positive Airway Pressure conditions: Pulmonary Function conditions: Older People studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patients were randomly assigned in a 1:1 ratio to either the O2-Max Trio or JPAP group through a computer-generated randomization list . primaryPurpose: TREATMENT masking: NONE maskingDescription: the treatment allocation was unblinded to both the patient and the staffs count: 60 type: ACTUAL name: Auto CPAP via nasal mask (JPAP machine) name: Constant CPAP via facial mask (O2-Max Trio system) measure: The oxygenation-PaO2/FiO2 measure: The forced vital capacity (FVC) measure: The forced expiratory volume in the first second-FEV1 measure: The FEV1/FVC ratio measure: The peak expiratory flow-PEF sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VietXo Friendship Hospital city: Hanoi zip: 12108 country: Vietnam lat: 21.0245 lon: 105.84117 hasResults: False
|
<|newrecord|> nctId: NCT06260813 id: S66277 briefTitle: Biomechanical and Morphological Characterization of PTTD acronym: PTTD overallStatus: RECRUITING date: 2022-08-22 date: 2028-08-01 date: 2028-08-01 date: 2024-02-15 date: 2024-02-15 name: Universitaire Ziekenhuizen KU Leuven class: OTHER briefSummary: Posterior tibial tendon dysfunction (PTTD) is a progressive condition of the tendon of the tibialis posterior muscle with symptoms of tendinopathy or even rupture. Functionally, it is associated with the inability to lock the mid foot and thus manifests itself as a main contributor to adult acquired flatfoot deformity.
|
Concerning treatment, clinical decision making is currently based on a classification integrating various parameters as pain, flexibility of the foot joints, the condition of the posterior tibial tendon assessed through ultrasound imaging and radiographic assessment of arthritic changes. Surprisingly, this classification does not consider any morphologic characteristics (the shape of a bone or joint) or functional, biomechanical characteristics of the foot and ankle, i.e. based on kinematics (e.g. range of motion) and/or kinetics (center of pressure, angular velocity, moment, power absorption and power generation of a joint).
|
Detailed biomechanical characteristics of the foot and ankle can be reliably collected by instrumented gait analysis wherein a 3D camera system is combined with a force plate and plantar pressure platform. Kinematic studies in the field of PTTD typically considered the foot as a structure consisting of three segments: hind foot, forefoot and hallux. Consequently, the mid foot segment (the Chopart and Lisfranc joints) has been neglected, although it is this segment that is particularly affected in PTTD patients.
|
The aim of this research is to overcome the limitations of the current classification system and treatment of PTTD patients, by complementing the current standard-of-care clinical assessment with better insight in the pathologic changes that occur in PTTD patients. conditions: Posterior Tibial Tendon Dysfunction studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective interventional study that includes PTTD patients (PTTD I, II and III) and a healthy control group. primaryPurpose: DIAGNOSTIC masking: SINGLE maskingDescription: PTTD patients (PTTD I, II and III) and a healthy control group. whoMasked: PARTICIPANT count: 100 type: ESTIMATED name: Radiography name: Ultrasound name: MRI name: CT-scan name: Gait analysis measure: Kinematic characteristics during Gait analysis measure: Center of pressure during Gait analysis measure: Angular velocity during Gait analysis measure: Moment during Gait analysis measure: Power absorption during Gait analysis measure: Power generation during Gait analysis measure: Bone morphology measure: American Orthopaedic Foot & Ankle Society (AOFAS) score measure: European Foot and Ankle Society (EFAS) score measure: 36-item Short Form Health Survey (SF36) measure: Visual Analogue Scale (VAS) pain measure: Visual Analogue Scale (VAS) satisfaction sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UZ Leuven status: RECRUITING city: Leuven state: Vlaams-Brabant zip: 3000 country: Belgium name: Sander Wuite role: CONTACT phone: +32 16 33 83 29 email: [email protected] name: Kevin Deschamps role: CONTACT phone: +32 16 33 88 27 email: [email protected] lat: 50.87959 lon: 4.70093 hasResults: False
|
<|newrecord|> nctId: NCT06260800 id: PI 23-3405 briefTitle: Spanish Version of Credibility and Expectancy Questionnaire in Patients With Musculoskeletal Injuries overallStatus: RECRUITING date: 2024-01-08 date: 2024-07-01 date: 2024-11-30 date: 2024-02-15 date: 2024-02-15 name: University of Valladolid class: OTHER briefSummary: Physiotherapy treatment of musculoskeletal injuries should be performed following the main clinical guidelines of person-centered care. Patients' perception of the abilities and facilities provided by physiotherapists boost a convenient therapeutic relationship. This relation is linked with more satisfaction and adherence during the treatment, as well as credibility and expectancy of the patient related to the treatment. Thus, Credibility and Expectancy questionnaire is normally used to assess that point. CEQ presents good psychometric properties when used in Physisiotherapy interventions, but there is not a spanish version of this questionaire. conditions: Validation Study studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 60 type: ESTIMATED name: Validation CEQ measure: Content validity measure: Construct validity measure: Reliability measure: Criterion validity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Silvia Lahuerta Martín status: RECRUITING city: Soria zip: 42004 country: Spain lat: 41.76401 lon: -2.46883 hasResults: False
|
<|newrecord|> nctId: NCT06260787 id: OBGY-202401.01 briefTitle: Clinical Profiles And In Vitro Fertilization Success overallStatus: COMPLETED date: 2023-01-01 date: 2023-03-31 date: 2023-12-31 date: 2024-02-15 date: 2024-02-15 name: Universitas Padjadjaran class: OTHER briefSummary: This research was carried out to determine if the IVF patients' clinical profile were connected with how successful in their getting pregnant. This was a cross-sectional study which recruited all patients, performed at a major fertility clinic in Indonesia. Our data collection period spanned between January 2017 and December 2021. conditions: in Vitro Fertilisation studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 223 type: ACTUAL name: In Vitro Fertilisation measure: Pregnancy rate sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran city: Bandung state: Jawa Barat zip: 40161 country: Indonesia lat: -6.92222 lon: 107.60694 hasResults: False
|
<|newrecord|> nctId: NCT06260774 id: TTX-MC138-002 briefTitle: Study of TTX-MC138 in Subjects With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-05-30 date: 2026-02-01 date: 2027-02-01 date: 2024-02-15 date: 2024-04-09 name: TransCode Therapeutics class: INDUSTRY briefSummary: A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Dose Escalation Study Design primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: TTX-MC138 measure: Dose Escalation - Adverse Events measure: Dose Escalation - Overall Response Rate (ORR) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06260761 id: Dh3108103/64 briefTitle: MIPO Versus Conventional Approach in Volar Locking Plate for Close Fractures Distal End Radius Under WALANT overallStatus: COMPLETED date: 2021-10-05 date: 2023-02-05 date: 2023-02-05 date: 2024-02-15 date: 2024-02-15 name: Police General Hospital, Thailand class: OTHER briefSummary: The goal of this clinical trial is to compare the Minimally Invasive Plate Osteosynthesis (MIPO) approach with conventional methods in volar locking plate treatment for distal end radius fractures under the Wide Awake Local Anesthesia No Tourniquet (WALANT) technique. The main question it aims to answer is: Does the MIPO approach provide better pain control than the conventional approach of volar locking plate fixation in distal radius fractures under WALANT? Participants will be requested to record their pain on the Visual Analog Scale (VAS), assess their functional scores, and undergo postoperative radiographic evaluations. Researchers will compare the MIPO group and the conventional group to determine the postoperative pain VAS scores, shedding light on the comparative effectiveness of the two approaches. conditions: Radius; Fracture, Lower or Distal End studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: prospective, parallel group, assessor-blinded, randomized controlled trial. randomized with computer generator number and use block-of-four. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The data collector, an orthopedic resident unaware of the surgical technique used, obtained information after operation. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 68 type: ACTUAL name: MIPO name: Conventional measure: Pain Visual analogue scale measure: Quick Disabilities of the Arm, Shoulder and Hand measure: Grip strength measure: Pinch strength measure: Range of motion measure: Aesthetics measure: Satisfy measure: Volar tile measure: ulnar variance measure: radial inclination measure: operation time measure: skin incision measure: morphine IV use measure: complication sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Police general hospital city: Pathum Wan state: Bangkok zip: 10330 country: Thailand lat: 13.73649 lon: 100.5239 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2021-10-05 uploadDate: 2024-02-04T06:00 filename: Prot_SAP_000.pdf size: 1309374 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2021-10-05 uploadDate: 2024-02-04T06:05 filename: ICF_001.pdf size: 80882 hasResults: False
|
<|newrecord|> nctId: NCT06260748 id: LBI-CDCA-001 id: 2023-505759-29-00 type: OTHER domain: EU Clinical Trials Register briefTitle: A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX) overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-11-30 date: 2025-12-31 date: 2024-02-15 date: 2024-02-15 name: Leadiant Biosciences, Inc. class: INDUSTRY briefSummary: This study is designed to demonstrate the beneficial effect of CDCA in the treatment of CTX-associated diarrhea in approximately 10 participants aged 2-75 years old with newly diagnosed CTX or suspected CTX who have never received treatment with CDCA. conditions: Cerebrotendinous Xanthomatoses studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 10 type: ESTIMATED name: Chenodeoxycholic acid name: Chenodeoxycholic acid Placebo measure: Change from baseline at Week 4 in average number of stools with a BSS score of 6 or 7 per day measure: Change in plasma cholestanol levels from baseline to Week 12 measure: Change in urine and/or plasma bile alcohol levels from baseline to Week 12 measure: Incidence of, severity/intensity of, and relationship to study drug of AEs measure: Incidence of, severity/intensity of, and relationship to study drug of SAEs measure: Incidence of, severity/intensity of AESIs measure: Incidence of, severity/intensity of, and changes in laboratory values measure: Incidence of, severity/intensity of, and changes in physical examination measure: Incidence of, severity/intensity of, and changes in vital signs measure: Number of participants with discontinuations due to AEs sex: ALL minimumAge: 2 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06260735 id: HS25897 (H2023:073) id: URGP#51472 type: OTHER_GRANT domain: University of Manitoba id: RGPIN-2015-05703 type: OTHER_GRANT domain: NSERC briefTitle: Non-invasive Spinal Cord Stimulation After Spinal Cord Injury acronym: SCI-ES-WALK overallStatus: RECRUITING date: 2023-06-15 date: 2024-08-15 date: 2024-11-15 date: 2024-02-15 date: 2024-02-15 name: University of Manitoba class: OTHER briefSummary: Spinal cord injury (SCI) is a central nervous system injury that often leads to motor dysfunction. Non-invasive electrical stimulation of the spinal cord has been recognized as a potential method of reactivating lost spinal neural networks to improve motor recovery and exercise response after SCI. Trans-spinal electrical stimulation (ts-ES) has been found to increase functional gains in people after SCI when applied in combination with other motor training protocols.
|
This project aims to evaluate the effects of non-invasive lumbar spinal cord electrical stimulation on the motor function of trunk and lower limbs in people with SCI after augmenting their locomotor training (treadmill stepping) with step-cycle-based electrical peripheral neural stimulation methods. conditions: Spinal Cord Injuries conditions: Spinal Cord Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Trans-spinal electrical stimulation name: Electrical muscle activation name: Treadmill walking measure: Neurophysiological markers or stepping measure: Electromyography (EMG) of ankle extensor muscles measure: Metabolic function testing measure: 6 Min Walk Test measure: SCIM-Spinal Cord Independence Measure- Mobility scores measure: Autonomic scores measure: Rate or Perceived Exertion (RPE) of Submaximal VO2 testing sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Manitoba status: RECRUITING city: Winnipeg state: Manitoba zip: R3E 0W2 country: Canada name: Katinka Stecina role: CONTACT phone: 204-789-3761 email: [email protected] lat: 49.8844 lon: -97.14704 hasResults: False
|
<|newrecord|> nctId: NCT06260722 id: 18805 id: J1I-MC-GZBZ type: OTHER domain: Eli Lilly and Company briefTitle: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) overallStatus: RECRUITING date: 2024-02-21 date: 2026-12-11 date: 2027-03-30 date: 2024-02-15 date: 2024-04-17 name: Eli Lilly and Company class: INDUSTRY briefSummary: The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits. conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 1250 type: ESTIMATED name: Retatrutide name: Semaglutide measure: Change from Baseline in Hemoglobin A1c (HbA1c) (%) measure: Change from Baseline in HbA1c (%) measure: Percentage of Participants Who Achieve HbA1c ≤ 6.5% measure: Percentage of Participants Who Achieve HbA1c < 5.7% measure: Percent Change from Baseline in Body Weight measure: Change from Baseline in Body Weight measure: Percentage of Participants Who Achieve Weight Reduction of ≥ 5% measure: Percentage of Participants Who Achieve Weight Reduction of ≥ 10% measure: Percentage of Participants Who Achieve Weight Reduction of ≥ 15% measure: Percentage of Participants Who Achieve HbA1c ≤ 6.5% and ≥ 10% Weight Reduction measure: Percent Change from Baseline in Triglycerides measure: Percent Change from Baseline in Non- high-density lipoprotein (HDL) Cholesterol measure: Change from Baseline in Systolic Blood Pressure (SBP) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Alabama - Department of Nutrition Sciences status: RECRUITING city: Birmingham state: Alabama zip: 35294 country: United States name: William Garvey role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 facility: Neighborhood Healthcare Institute of Health status: RECRUITING city: Escondido state: California zip: 92025 country: United States name: James Schultz role: PRINCIPAL_INVESTIGATOR lat: 33.11921 lon: -117.08642 facility: Long Beach Research Institute status: RECRUITING city: Long Beach state: California zip: 90805 country: United States name: Ashley Duzik role: PRINCIPAL_INVESTIGATOR lat: 33.76696 lon: -118.18923 facility: Rancho Cucamonga Clinical Research status: RECRUITING city: Rancho Cucamonga state: California zip: 91730 country: United States name: Steven Barag role: PRINCIPAL_INVESTIGATOR lat: 34.1064 lon: -117.59311 facility: University of Colorado Anschutz Medical Campus status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: Neda Rasouli role: PRINCIPAL_INVESTIGATOR lat: 39.72943 lon: -104.83192 facility: Arrow Clinical Trials status: RECRUITING city: Daytona Beach state: Florida zip: 32117 country: United States name: David Billmeier role: PRINCIPAL_INVESTIGATOR lat: 29.21081 lon: -81.02283 facility: New Age Medical Research Corporation status: RECRUITING city: Miami state: Florida zip: 33186 country: United States name: Janet Gersten role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 facility: South Broward Research status: RECRUITING city: Miramar state: Florida zip: 33027 country: United States name: Kenneth Blaze role: PRINCIPAL_INVESTIGATOR lat: 25.98731 lon: -80.23227 facility: Clinical Research of Central Florida status: RECRUITING city: Winter Haven state: Florida zip: 33880 country: United States name: Eduardo Torres role: PRINCIPAL_INVESTIGATOR lat: 28.02224 lon: -81.73286 facility: Herman Clinical Research status: RECRUITING city: Suwanee state: Georgia zip: 30024 country: United States name: Lee Herman role: PRINCIPAL_INVESTIGATOR lat: 34.05149 lon: -84.0713 facility: Pacific Diabetes & Endocrine Center status: RECRUITING city: Honolulu state: Hawaii zip: 96813 country: United States name: ALAN PARSA role: PRINCIPAL_INVESTIGATOR lat: 21.30694 lon: -157.85833 facility: Rocky Mountain Clinical Research status: RECRUITING city: Idaho Falls state: Idaho zip: 83404 country: United States name: Kevin Prier role: PRINCIPAL_INVESTIGATOR lat: 43.46658 lon: -112.03414 facility: Deaconess Clinic - Gateway Health Center status: NOT_YET_RECRUITING city: Newburgh state: Indiana zip: 47630 country: United States name: Renee Galen role: PRINCIPAL_INVESTIGATOR lat: 37.94449 lon: -87.40529 facility: IMA Clinical Research Monroe - Armand status: RECRUITING city: Monroe state: Louisiana zip: 71201 country: United States name: Clinton Guillory role: PRINCIPAL_INVESTIGATOR lat: 32.50931 lon: -92.1193 facility: MedStar Health Research Institute (MedStar Physician Based Research Network) status: RECRUITING city: Hyattsville state: Maryland zip: 20782 country: United States name: Jean Park role: PRINCIPAL_INVESTIGATOR lat: 38.95594 lon: -76.94553 facility: Brigham and Women's Hospital Diabetes Program status: RECRUITING city: Boston state: Massachusetts zip: 02115 country: United States name: Vanita Aroda role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: NECCR PrimaCare Research status: RECRUITING city: Fall River state: Massachusetts zip: 02721 country: United States name: Ehab Sorial role: PRINCIPAL_INVESTIGATOR lat: 41.70149 lon: -71.15505 facility: Arcturus Healthcare , PLC, Troy Internal Medicine Research Division status: RECRUITING city: Troy state: Michigan zip: 48098 country: United States name: Neil Fraser role: PRINCIPAL_INVESTIGATOR lat: 42.60559 lon: -83.14993 facility: Palm Research Center Tenaya status: RECRUITING city: Las Vegas state: Nevada zip: 89128 country: United States name: Samer Nakhle role: PRINCIPAL_INVESTIGATOR lat: 36.17497 lon: -115.13722 facility: NYC Research INC status: RECRUITING city: Long Island City state: New York zip: 11106 country: United States name: Anastasios Manessis role: PRINCIPAL_INVESTIGATOR lat: 40.74482 lon: -73.94875 facility: Medication Management status: RECRUITING city: Greensboro state: North Carolina zip: 27405 country: United States name: James Franklin role: PRINCIPAL_INVESTIGATOR lat: 36.07264 lon: -79.79198 facility: Remington Davis Clinical Research status: RECRUITING city: Columbus state: Ohio zip: 43215 country: United States name: Elena Christofides role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 facility: Intend Research, LLC status: RECRUITING city: Norman state: Oklahoma zip: 73069 country: United States name: Lisa Connery role: PRINCIPAL_INVESTIGATOR lat: 35.22257 lon: -97.43948 facility: Central States Research status: RECRUITING city: Tulsa state: Oklahoma zip: 74136 country: United States name: Sarah Land role: PRINCIPAL_INVESTIGATOR lat: 36.15398 lon: -95.99277 facility: The Corvallis Clinic, P.C. status: RECRUITING city: Corvallis state: Oregon zip: 97330 country: United States name: Brian Curtis role: PRINCIPAL_INVESTIGATOR lat: 44.56457 lon: -123.26204 facility: Thomas Jefferson University Hospital status: NOT_YET_RECRUITING city: Philadelphia state: Pennsylvania zip: 19107 country: United States name: Serge Jabbour role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 facility: Dallas Diabetes Research Center status: RECRUITING city: Dallas state: Texas zip: 75230 country: United States name: Julio Rosenstock role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 facility: Valley Institute of Research - Fort Worth status: RECRUITING city: Fort Worth state: Texas zip: 76164 country: United States name: alex guevara role: PRINCIPAL_INVESTIGATOR lat: 32.72541 lon: -97.32085 facility: Juno Research status: RECRUITING city: Houston state: Texas zip: 77040 country: United States name: Damaris Vega role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 facility: Southern Endocrinology Associates status: RECRUITING city: Mesquite state: Texas zip: 75149 country: United States name: Sumana Gangi role: PRINCIPAL_INVESTIGATOR lat: 32.7668 lon: -96.59916 facility: Texas Valley Clinical Research status: RECRUITING city: Weslaco state: Texas zip: 78596 country: United States name: Eduardo Luna role: PRINCIPAL_INVESTIGATOR lat: 26.15952 lon: -97.99084 facility: Medrasa Clinical Research status: RECRUITING city: Wylie state: Texas zip: 75098 country: United States name: Tanvir Ahmad role: PRINCIPAL_INVESTIGATOR lat: 33.01512 lon: -96.53888 facility: Central Washington Health Services Association d/b/a Confluence Health status: RECRUITING city: Wenatchee state: Washington zip: 98801 country: United States name: Anton Grasch role: PRINCIPAL_INVESTIGATOR lat: 47.42346 lon: -120.31035 facility: Exemplar Research status: RECRUITING city: Morgantown state: West Virginia zip: 26505 country: United States name: WARD PAINE role: PRINCIPAL_INVESTIGATOR lat: 39.62953 lon: -79.9559 facility: CARE - Centro de Alergia y Enfermedades Respiratorias status: NOT_YET_RECRUITING city: Ciudad Autónoma de Buenos Aires state: Buenos Aires zip: 1414 country: Argentina name: Hernan Finkelstein role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Stat Research S.A. status: NOT_YET_RECRUITING city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1023AAB country: Argentina name: Lucas Gutnisky role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: CIPREC status: NOT_YET_RECRUITING city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1061AAS country: Argentina name: Cesar Zaidman role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Centro Médico Viamonte status: RECRUITING city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1120AAC country: Argentina name: Diego Aizenberg role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Mautalen Salud e Investigación status: NOT_YET_RECRUITING city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1128AAF country: Argentina name: José Fretes role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: CEMEDIAB status: NOT_YET_RECRUITING city: C.a.b.a. state: Ciudad Autónoma De Buenos Aires zip: C1205AAO country: Argentina name: Alejandro Chertkoff role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Instituto Centenario status: NOT_YET_RECRUITING city: Caba state: Ciudad Autónoma De Buenos Aires zip: 1204 country: Argentina name: SUSANA SALZBERG role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada status: NOT_YET_RECRUITING city: Ciudad Autonoma de Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1425AGC country: Argentina name: Antonela Mainardi role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Centro Medico Privado San Vicente Diabetes status: NOT_YET_RECRUITING city: Cordoba state: Córdoba zip: 5006 country: Argentina name: Cecilia Luquez role: PRINCIPAL_INVESTIGATOR lat: -31.4135 lon: -64.18105 facility: CIPADI - Centro Integral de Prevencion y Atencion en Diabetes status: RECRUITING city: Godoy Cruz state: Mendoza zip: 5501 country: Argentina name: Pedro Rosario Fabian Calella role: PRINCIPAL_INVESTIGATOR lat: -32.92863 lon: -68.8351 facility: Centro de Investigaciones Clínicas Baigorria status: RECRUITING city: Granadero Baigorria state: Santa Fe zip: 2152 country: Argentina name: Juan Escalante role: PRINCIPAL_INVESTIGATOR lat: -32.85683 lon: -60.71754 facility: Instituto de Investigaciones Clinicas Rosario status: NOT_YET_RECRUITING city: Rosario state: Santa Fe zip: S2000CVD country: Argentina name: Maximiliano Sicer role: PRINCIPAL_INVESTIGATOR lat: -32.94682 lon: -60.63932 facility: Fundación Respirar status: RECRUITING city: Buenos Aires zip: C1426ABP country: Argentina name: Maria De Salvo role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Centro de Investigaciones Metabólicas (CINME) status: NOT_YET_RECRUITING city: Ciudad Autónoma de Buenos Aires zip: C1056ABJ country: Argentina name: Federico Perez Manghi role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Centro Diabetológico Dr. Waitman status: NOT_YET_RECRUITING city: Córdoba zip: 5000 country: Argentina name: JOSE POZZI role: PRINCIPAL_INVESTIGATOR lat: -31.4135 lon: -64.18105 facility: University of Calgary - Clinical Trials Unit status: NOT_YET_RECRUITING city: Calgary state: Alberta zip: T2T 5C7 country: Canada name: Ronald Sigal role: PRINCIPAL_INVESTIGATOR lat: 51.05011 lon: -114.08529 facility: Alberta Diabetes Institute status: NOT_YET_RECRUITING city: Edmonton state: Alberta zip: T6G 2E1 country: Canada name: Peter Senior role: PRINCIPAL_INVESTIGATOR lat: 53.55014 lon: -113.46871 facility: Aggarwal and Associates Limited status: RECRUITING city: Brampton state: Ontario zip: L6T 0G1 country: Canada name: Naresh Aggarwal role: PRINCIPAL_INVESTIGATOR lat: 43.68341 lon: -79.76633 facility: Dr. Steven V. Zizzo Medicine Professional Corporation status: RECRUITING city: Hamilton state: Ontario zip: L8J 0B6 country: Canada name: Steven Zizzo role: PRINCIPAL_INVESTIGATOR lat: 43.25011 lon: -79.84963 facility: Wharton Medical Clinic status: NOT_YET_RECRUITING city: Hamilton state: Ontario zip: L8L 5G8 country: Canada name: Sean Wharton role: PRINCIPAL_INVESTIGATOR lat: 43.25011 lon: -79.84963 facility: Hamilton Medical Research Group status: RECRUITING city: Hamilton state: Ontario zip: L8M 1K7 country: Canada name: Richard Tytus role: PRINCIPAL_INVESTIGATOR lat: 43.25011 lon: -79.84963 facility: Bluewater Clinical Research Group Inc. status: NOT_YET_RECRUITING city: Sarnia state: Ontario zip: N7T 4X3 country: Canada name: John O'Mahony role: PRINCIPAL_INVESTIGATOR lat: 42.97866 lon: -82.40407 facility: Prime Health Clinical Research status: NOT_YET_RECRUITING city: Toronto state: Ontario zip: M4S 1Y2 country: Canada name: Iris Shasha Gorfinkel role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 facility: Maple Leaf Research status: RECRUITING city: Toronto state: Ontario zip: M5G 1K2 country: Canada name: Graham Smith role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 facility: Private Practice - Dr. Nigel Jagan status: RECRUITING city: Whitby state: Ontario zip: L1N 2L1 country: Canada name: Nigel Jagan role: PRINCIPAL_INVESTIGATOR lat: 43.88342 lon: -78.93287 facility: 9109-0126 Quebec Inc. status: RECRUITING city: Montreal state: Quebec zip: H4N 2W2 country: Canada name: Ronald Akhras role: PRINCIPAL_INVESTIGATOR lat: 45.50884 lon: -73.58781 facility: RM Pharma Specialists status: NOT_YET_RECRUITING city: Mexico City state: Distrito Federal zip: 03100 country: Mexico name: Mariana Crespo role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Hospital de Jésus, I.A.P. status: NOT_YET_RECRUITING city: Mexico City state: Distrito Federal zip: 06090 country: Mexico name: Efrain Villeda Espinosa role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares status: NOT_YET_RECRUITING city: Mexico City state: Distrito Federal zip: 11650 country: Mexico name: Melchor Alpizar Salazar role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Diseno y Planeacion en Investigacion Medica status: NOT_YET_RECRUITING city: Guadalajara state: Jalisco zip: 44130 country: Mexico name: Cesar Calvo role: PRINCIPAL_INVESTIGATOR lat: 20.66682 lon: -103.39182 facility: Private Practice - Dr. Arechavaleta Granell Maria del Rosario status: NOT_YET_RECRUITING city: Guadalajara state: Jalisco zip: 44670 country: Mexico name: Maria Arechavaleta Granell role: PRINCIPAL_INVESTIGATOR lat: 20.66682 lon: -103.39182 facility: Instituto de Diabetes, Obesidad y Nutricion status: NOT_YET_RECRUITING city: Cuernavaca state: Morelos zip: 62250 country: Mexico name: Leobardo Sauque Reyna role: PRINCIPAL_INVESTIGATOR lat: 18.9261 lon: -99.23075 facility: Cardiolink Clin Trials status: NOT_YET_RECRUITING city: Monterrey state: Nuevo León zip: 64060 country: Mexico name: Elías García role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: Clínica García Flores SC status: NOT_YET_RECRUITING city: Monterrey state: Nuevo León zip: 64610 country: Mexico name: Pedro Garcia role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: Enclifar Ensayos Clínicos Farmacológicos Sc status: NOT_YET_RECRUITING city: Chihuahua zip: 31110 country: Mexico name: Luis Nevarez role: PRINCIPAL_INVESTIGATOR lat: 28.63528 lon: -106.08889 facility: Instituto Veracruzano en Investigación Clínica S.C. status: NOT_YET_RECRUITING city: Veracruz zip: 91851 country: Mexico name: Rosa Luna Ceballos role: PRINCIPAL_INVESTIGATOR lat: 19.18095 lon: -96.1429 facility: Advanced Clinical Research, LLC status: RECRUITING city: Bayamón zip: 00959 country: Puerto Rico name: Angel Comulada-Rivera role: PRINCIPAL_INVESTIGATOR lat: 18.39856 lon: -66.15572 facility: GCM Medical Group, PSC - Hato Rey Site status: RECRUITING city: San Juan zip: 00917 country: Puerto Rico name: Gregorio Cortes-Maisonet role: PRINCIPAL_INVESTIGATOR lat: 18.46633 lon: -66.10572 hasResults: False
|
<|newrecord|> nctId: NCT06260709 id: NN6019-7565 id: 2022-502605-15-00 type: OTHER domain: European Medical Agency (EMA) id: U1111-1284-5820 type: OTHER domain: World Health Organization (WHO) briefTitle: A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis overallStatus: RECRUITING date: 2024-02-20 date: 2028-02-29 date: 2028-02-29 date: 2024-02-15 date: 2024-04-26 name: Novo Nordisk A/S class: INDUSTRY briefSummary: This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for up to 157 weeks (36 months/3 years). conditions: Transthyretin Amyloid Cardiomyopathy (ATTR CM) studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: NNC6019-0001 measure: Number of Treatment Emergent Adverse Events measure: Change in 6-Minute Walk Test (6MWT) measure: Change in N-terminal-pro brain natriuretic peptide (NT-proBNP) measure: Change in Myocardial Extracellular Volume (ECV) measure: Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) measure: Change in Troponin I measure: Change in Global Longitudinal Strain (GLS) on Echocardiography sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic Arizona status: NOT_YET_RECRUITING city: Phoenix state: Arizona zip: 85054 country: United States lat: 33.44838 lon: -112.07404 facility: Cedars-Sinai Medical Center_Los Angeles status: NOT_YET_RECRUITING city: Beverly Hills state: California zip: 90211 country: United States lat: 34.07362 lon: -118.40036 facility: Stanford Hlth Cre-Boswell Clin status: RECRUITING city: Stanford state: California zip: 94305 country: United States lat: 37.42411 lon: -122.16608 facility: Mayo Clinic Jacksonville status: NOT_YET_RECRUITING city: Jacksonville state: Florida zip: 32224 country: United States lat: 30.33218 lon: -81.65565 facility: NW Univ-Bluhm Cardiovasc Inst status: NOT_YET_RECRUITING city: Evanston state: Illinois zip: 60208 country: United States lat: 42.04114 lon: -87.69006 facility: Univ of MD Schl of Med status: RECRUITING city: Baltimore state: Maryland zip: 21201 country: United States lat: 39.29038 lon: -76.61219 facility: Mayo Clinic Rochester status: NOT_YET_RECRUITING city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 facility: University of Calgary_Cardiology status: NOT_YET_RECRUITING city: Calgary state: Alberta zip: T2N 4Z6 country: Canada lat: 51.05011 lon: -114.08529 facility: Ctr for Cardiovascular Innovation status: NOT_YET_RECRUITING city: Vancouver state: British Columbia zip: V5Z 1M9 country: Canada lat: 49.24966 lon: -123.11934 facility: II. interni klinika VFN - Kardiologie a angiologie status: NOT_YET_RECRUITING city: Praha 2 zip: 12808 country: Czechia lat: 50.08804 lon: 14.42076 facility: Ap-Hp-Hopital Henri Mondor status: NOT_YET_RECRUITING city: Créteil zip: 94000 country: France lat: 48.78333 lon: 2.46667 facility: Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-1 status: NOT_YET_RECRUITING city: Toulouse Cedex 9 zip: 31059 country: France lat: 43.60426 lon: 1.44367 facility: Universitätsklinik Heidelberg Innere Medizin III Kardiologie, Angiologie, Pneumologie status: NOT_YET_RECRUITING city: Heidelberg zip: 69120 country: Germany lat: 49.40768 lon: 8.69079 facility: LMU Klinikum München Klinik und Poliklinik 1 status: NOT_YET_RECRUITING city: München zip: 81377 country: Germany lat: 48.13743 lon: 11.57549 facility: Uniklinik Münster, Klinik für Kardiologie I status: NOT_YET_RECRUITING city: Münster zip: 48149 country: Germany lat: 51.96236 lon: 7.62571 facility: Universitatsklinikum Wurzburg AöR status: NOT_YET_RECRUITING city: Würzburg zip: 97078 country: Germany lat: 49.79391 lon: 9.95121 facility: Fondazione CNR-Regione Toscana Gabriele Monasterio status: NOT_YET_RECRUITING city: Pisa state: Pi zip: 56124 country: Italy lat: 43.70853 lon: 10.4036 facility: Centro per lo Studio e la Cura delle Amiloidosi Sistemiche Fondazione IRCCS Policlinico San Matteo status: NOT_YET_RECRUITING city: Pavia state: PV zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 facility: UMC Groningen status: NOT_YET_RECRUITING city: Groningen zip: 9713 GZ country: Netherlands lat: 53.21917 lon: 6.56667 facility: Universitair Medisch Centrum Utrecht status: NOT_YET_RECRUITING city: Utrecht zip: 3584 CX country: Netherlands lat: 52.09083 lon: 5.12222 facility: Hospital da Senhora da Oliveira - Guimarães status: NOT_YET_RECRUITING city: Guimarães zip: 4835-044 country: Portugal lat: 41.44443 lon: -8.29619 facility: Centro Hospitalar de Trás-os-Montes e Alto Douro status: NOT_YET_RECRUITING city: Vila Real zip: 5000-508 country: Portugal lat: 41.30062 lon: -7.74413 facility: Hospital Universitario Puerta de Hierro Majadahonda status: NOT_YET_RECRUITING city: Majadahonda state: Madrid zip: 28222 country: Spain lat: 40.47353 lon: -3.87182 hasResults: False
|
<|newrecord|> nctId: NCT06260696 id: DAS-7626 id: U1111-1282-5512 type: OTHER domain: World Health Organization (WHO) briefTitle: Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender acronym: ASPECT - APAC overallStatus: COMPLETED date: 2023-08-10 date: 2023-10-05 date: 2023-10-05 date: 2024-02-15 date: 2024-02-15 name: Novo Nordisk A/S class: INDUSTRY briefSummary: The purpose of this survey is to collect information for scientific research and to identify the impact of overweight and obesity on health-related quality of life. conditions: Overweight conditions: Obesity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 3000 type: ACTUAL name: No treatment is given measure: Score on IWQOL-Lite validated sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Novo Nordisk Investigational Site city: Dubai country: United Arab Emirates lat: 25.0657 lon: 55.17128 hasResults: False
|
<|newrecord|> nctId: NCT06260683 id: OSU-22240 id: NCI-2023-04102 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: R01DA057327 type: NIH link: https://reporter.nih.gov/quickSearch/R01DA057327 briefTitle: A Comprehensive Evaluation of Tobacco-Flavored vs. Non-Tobacco Flavored E-cigarettes on Smoking Behavior overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2027-04-29 date: 2027-04-29 date: 2024-02-15 date: 2024-04-03 name: Ohio State University Comprehensive Cancer Center class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: This clinical trial compares the use of tobacco flavored electronic cigarettes (ECs) to non-tobacco flavored ECs on smoking behavior in current cigarette smokers to use of nicotine replacement therapy (patches and lozenges). ECs may reduce cigarette craving and withdrawal symptoms, increase motivation and confidence to stop cigarette smoking, and decrease cigarette smoking and dependence. By comparing participants' preferred flavor ECs (PEC) to tobacco flavor ECs (TEC) to NRT, researchers hope to determine the effect of EC flavors on appeal and use, and learn how ECs affect smoking behaviors and health. conditions: Cigarette Smoking-Related Carcinoma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 1500 type: ESTIMATED name: Nicotine Replacement name: Questionnaire Administration name: Vaping name: Vaping measure: Biochemically verified 7-day point prevalence abstinence from cigarettes measure: Switching rate measure: Cigarettes smoked per day measure: Change in nicotine dependence measure: Changes in cigarette craving and nicotine withdrawal measure: Number of days used measure: Product appeal measure: Continued purchase and use of ECs sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ohio State University Comprehensive Cancer Center city: Columbus state: Ohio zip: 43210 country: United States name: Theodore L. Wagener, PhD role: CONTACT email: [email protected] name: Theodore L. Wagener, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
|
<|newrecord|> nctId: NCT06260670 id: CP0004 briefTitle: FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation acronym: FLOW EVAL-AF overallStatus: COMPLETED date: 2022-09-01 date: 2022-10-28 date: 2022-10-28 date: 2024-02-15 date: 2024-02-15 name: Ablacon, Inc. class: INDUSTRY briefSummary: FLOW EVAL-AF is a prospective, observational, single center pilot trial. The FLOW EVAL-AF trial is designed to identify driver sources in patients with persistent or longstanding persistent AF using EGF mapping and describe the activation patterns observed from concomitant high density mapping of those regions. conditions: Persistent Atrial Fibrillation conditions: Longstanding Persistent Atrial Fibrillation conditions: Atrial Fibrillation, Persistent conditions: Arrhythmias, Cardiac studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 10 type: ACTUAL name: Electrographic Flow™ Mapping using Ablamap® Software and FIRMap™ Catheter measure: Descriptive correlation of electrogram patterns sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Herz-und Diabeteszentrum NRW (Clinic of Ruhr University of Bochum) city: Bad Oeynhausen state: North Rhine-Westphalia zip: 32545 country: Germany lat: 52.20699 lon: 8.80365 hasResults: False
|
<|newrecord|> nctId: NCT06260657 id: 2021PI124 briefTitle: Search for Olfactory Cells Within the Fetal Ethmoid Epithelium acronym: COEF overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-10 date: 2025-10 date: 2024-02-15 date: 2024-02-15 name: Central Hospital, Nancy, France class: OTHER briefSummary: The recent rhinological functional approach known as "Evo-Devo" leads us to consider the nose not as a single organ, but as the construction of a specifically olfactory organ within which functional respiratory structures have developed over the course of species evolution in the same way they develop during human embryogenesis.
|
In adult humans, the olfactory structures are limited to two narrow regions situated at the upper part of the nasal passages known as olfactory clefts. Nevertheless, phylogenetic evidence indicates that these olfactory clefts are vestiges of an olfactory organ that once occupied the entire ethmoid bone in the front of the skull base.
|
The hypothesis of this study posits that, during the embryological development of the ethmoid bone, it would initially be covered with olfactory mucosa, which would gradually diminish as the lateral masses of the ethmoid formed, eventually persisting exclusively within the olfactory clefts of the ethmoid by the conclusion of the first trimester (end of organogenesis). Besides their fundamental interest, the results of this study could help understand the still unknown pathogenesis of nasal polyposis, a chronic anosmic disease with a prevalence of 2 to 4% in the French and European population.
|
This study requires a series of ethmoidal samples from human fetuses at various ages between 7 and 15 weeks of gestational age. Specific immunohistological labeling techniques under standard optical microscopy will be used to search for and quantify olfactory nerve cells within the fetal ethmoidal mucosa. conditions: Fetal Ethmoidal Mucosa studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Histological analysis on fetal ethmoids measure: Immunohistological positive signal of primary olfactive neurons measure: Concentration of primary olfactory neurons immunohistological signals sex: ALL minimumAge: 7 Weeks maximumAge: 15 Weeks stdAges: CHILD facility: Centre Hospitalier Régional Universitaire - Service ORL city: Nancy country: France name: Roger Jankowski, MD/PhD role: CONTACT email: [email protected] lat: 48.68439 lon: 6.18496 hasResults: False
|
<|newrecord|> nctId: NCT06260644 id: Repairing defective composite briefTitle: Evaluation of Using Self-adhering Flowable Resin Composite in Repairing Old Defective Resin Composite Restorations Over 18 Months Follow up. (A Randomized Clinical Trial) overallStatus: ACTIVE_NOT_RECRUITING date: 2024-02-01 date: 2025-09 date: 2025-10 date: 2024-02-15 date: 2024-02-15 name: Cairo University class: OTHER briefSummary: This research proposal is evaluating the clinical performance of using self-adhering flowable resin composite in repairing old occlusal defective resin composite versus conventional flowable resin composite restoration over 18 months. conditions: Occlusal Caries studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: parallel assignment primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: double ( participants, outcomes assessor) participants and both assessors will be blind to the type of material used whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 34 type: ESTIMATED name: VertiseTM flowable composite (Kerr,USA) measure: Restoration clinical performance using FDI criteria sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: Faculty of Dentistry city: Cairo zip: 113311 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
|
<|newrecord|> nctId: NCT06260631 id: P.T.REC/012/004807 briefTitle: Efficacy of High-intensity Laser Acupuncture in Patients With Chronic, Non-specific Low Back Pain overallStatus: RECRUITING date: 2024-02-25 date: 2024-08 date: 2024-08 date: 2024-02-15 date: 2024-04-26 name: Cairo University class: OTHER name: King Khalid University briefSummary: The purpose of this study is to investigate the efficacy of high-intensity laser acupuncture on peak torque, power of trunk extensors and flexors, back pain, range of motion, function, and satisfaction in patients with chronic nonspecific low back pain (CNLBP). conditions: Chronic Nonspecific Low-back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: high-intensity laser acupuncture and exercise therapy program primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: random generator whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: high-intensity laser acupuncture and Exercise therapy program name: Sham laser acupuncture measure: peak torque measure: peak torque measure: Average Power measure: Average Power measure: Pain Intensity measure: Pain Intensity measure: lumbar flexion and extension ROM assessment measure: lumbar flexion and extension ROM assessment measure: Disability measure: Disability measure: patient Satisfaction measure: patient Satisfaction sex: ALL minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: Doaa Ayoub Elimy status: RECRUITING city: Giza zip: 11251 country: Egypt name: Doaa A Elimy, lecturer role: CONTACT phone: 00201066474654 email: [email protected] lat: 30.00808 lon: 31.21093 hasResults: False
|
<|newrecord|> nctId: NCT06260618 id: 2021/HRE00065 briefTitle: Effect of Chitodex Gel in Tympanoplasty Surgery overallStatus: RECRUITING date: 2021-11-20 date: 2024-05-13 date: 2024-05-13 date: 2024-02-15 date: 2024-02-20 name: Central Adelaide Local Health Network Incorporated class: OTHER_GOV name: University of Adelaide briefSummary: The general purpose of this study is to compare Chitosan-dextran (Chitodex) gel versus current standard of care, Gelfoam, as a middle ear (ME) and external auditory canal (EAC) packing agent as part of tympanoplasty procedures to close tympanic membrane perforations (TMP). conditions: Tympanic Membrane Perforation conditions: Tympanic Membrane Inflammation conditions: Surgery conditions: Otitis Media studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single blinded randomised clinical trial primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Masked: The people receiving the treatment/s, The people analysing the results/data Unmasked: The surgeon administering the treatment. whoMasked: PARTICIPANT count: 44 type: ESTIMATED name: Gelfoam name: Chitodex measure: Number of participants with tympanic membrane closure measure: rate of tympanic membrane closure measure: Number of participants with improved hearing measure: Number of participants with improved eardrum function measure: Ease of use of product compared to active comparator - surgeon feedback measure: Time taken to complete surgery measure: Number of Participants with improved quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Queen Elizabeth Hospital status: RECRUITING city: Adelaide state: South Australia zip: 5011 country: Australia name: Prof Peter John Wormald, MD role: CONTACT phone: +61 8 8222 7158 email: [email protected] name: Emma Barry, BSc (Hons) role: CONTACT phone: +61 8 8222 7158 email: [email protected] name: Prof Peter John Wormald, MD role: PRINCIPAL_INVESTIGATOR lat: -34.92866 lon: 138.59863 facility: The Memorial Hospital status: RECRUITING city: North Adelaide state: South Australia zip: 5006 country: Australia name: Prof Peter John Wormald, MD role: CONTACT phone: +61 8 8222 7158 email: [email protected] lat: -34.90733 lon: 138.59141 hasResults: False
|
<|newrecord|> nctId: NCT06260605 id: Burcu Bayrak 1 id: Burcu type: REGISTRY domain: Bayrak briefTitle: Complications of Diabetes With Puzzles acronym: Diabetes with overallStatus: COMPLETED date: 2023-12-19 date: 2024-02-20 date: 2024-03-04 date: 2024-02-15 date: 2024-03-07 name: Bilecik Seyh Edebali Universitesi class: OTHER briefSummary: In this study, it was aimed to investigate the effect of diabetes complications training on endocrine system diseases and nursing care in the Internal Medicine Nursing course on the knowledge level of nursing students. conditions: Diabetes Complications studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 110 type: ACTUAL name: Education measure: Education sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Bilecik Şeyh Edebali University city: Bilecik state: Merkez country: Turkey lat: 40.14192 lon: 29.97932 hasResults: False
|
<|newrecord|> nctId: NCT06260592 id: Aysun Acun 4 briefTitle: Ethical Attitude and Humanistic Acting Skills of Intensive Care Nurses overallStatus: RECRUITING date: 2024-02-06 date: 2024-03 date: 2024-03 date: 2024-02-15 date: 2024-02-15 name: Bilecik Seyh Edebali Universitesi class: OTHER briefSummary: Today, rapidly developing technology and changing treatment and care conditions increase the tendency towards ethical values both as an intellectual concept and as a moral guide. The nursing profession, which focuses on people in ethical terms, is also performed by people. This situation brings with it many ethical dilemmas in areas where health care services are provided. In ICUs, long and critical treatments of patients, differences of opinion between the medical team and the institution, non-compliance with patient rights, difficulties in terminal patient care, procedures performed without the patient\'s consent, distribution of limited medical resources, unethical attitudes and attitudes of nurse colleagues, Many issues such as long-term exposure to stressors and constant alarm sounds can cause mental distress and negative emotions in intensive care nurses. One of the effective ways to increase the quality of care provided by nurses is humanistic practice ability. The presence of humanistic practice ability provides more realistic, human-centered nursing care, improves the quality of life of patients, and also positively affects health expenditures. conditions: Humanistic Care Skills studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 400 type: ESTIMATED measure: Ethical compliance of nurses in the intensive care unit measure: Humanistic care skills of nurses in the intensive care unit sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bilecik Şeyh Edebali University status: RECRUITING city: Bilecik zip: 11000 country: Turkey name: Aysun Acun, PhD role: CONTACT phone: +905072104506 email: [email protected] name: Aysun Acun, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.14192 lon: 29.97932 hasResults: False
|
<|newrecord|> nctId: NCT06260579 id: S-number 66153 id: S006722N type: OTHER_GRANT domain: Research Foundation Flanders - SBO project briefTitle: Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity acronym: PHOENIX-Kidney overallStatus: RECRUITING date: 2022-11-14 date: 2025-09-30 date: 2029-12 date: 2024-02-15 date: 2024-02-15 name: KU Leuven class: OTHER name: University Ghent briefSummary: This multicentre two-phased RCT aims to evaluate implementation potential, cost-effectiveness, effectiveness, and the role of exercise intensity of a home-based exercise and physical activity intervention to improve de novo kidney transplant recipients' physical fitness, cardiovascular health, gut microbiome characteristics, and health-related quality of life. The first phase of this study comprehends a six-month exercise training intervention. Patients will be randomized into (i) a sham intervention consisting of low-intensity balance and stretching exercises (LIT), (ii) a moderate-intensity aerobic and strength training intervention (MIT), or (iii) a moderate- and high-intensity aerobic and strength training intervention (MHIT). The second phase of this study comprehends a physical activity maintenance intervention provided to MIT and MHIT but not LIT. A total of 147 de novo kidney transplant recipients will be recruited from two independent Belgian transplant centres i.e. UZ Leuven and UZ Ghent. conditions: Physical Activity conditions: Exercise Training conditions: Kidney Transplantation conditions: Physical Fitness conditions: Cardiovascular Health conditions: Gut Microbiome conditions: Health-related Quality of Life conditions: Implementation conditions: Cost-effectiveness studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel group randomized controlled trial primaryPurpose: OTHER masking: SINGLE maskingDescription: Outcome assessors are blinded to the group allocation of the patients. Due to the nature of the intervention, blinding of the patients is not possible. However, a sham training intervention is provided to the control group. whoMasked: OUTCOMES_ASSESSOR count: 147 type: ESTIMATED name: Exercise/physical activity measure: Changes in peak oxygen consumption (VO2peak) measure: Health-related physical fitness sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UZ Ghent status: RECRUITING city: Ghent zip: 9000 country: Belgium name: Calders Patrick, PhD role: CONTACT lat: 51.05 lon: 3.71667 facility: UZ Leuven status: RECRUITING city: Leuven zip: 3000 country: Belgium name: Amaryllis Van Craenenbroeck, MD, PhD role: CONTACT lat: 50.87959 lon: 4.70093 hasResults: False
|
<|newrecord|> nctId: NCT06260566 id: H-52570 briefTitle: Tolerability of Enteral NAC in Infants overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-02 date: 2027-02 date: 2024-02-15 date: 2024-04-15 name: Sanjiv Harpavat class: OTHER name: Baylor College of Medicine briefSummary: Biliary atresia (BA) is a neonatal liver disease characterized by impaired bile flow and is the most common indication for pediatric liver transplantation. BA can be treated with the Kasai portoenterostomy (KP), a procedure that attempts to restore bile flow and slow disease progression. However, success of the KP procedure is quite variable, and lack of adjuvant medical therapies following KP is a major gap in pediatric hepatology.
|
This study begins to explore oral N-acetylcysteine (NAC) as a potential medical therapy in BA by determining whether an oral formulation can be given to infants. The primary objective is to determine tolerability of the oral NAC formulation. The primary outcome is tolerating at least 3 out of 4 total doses without emesis. The Bayesian Optimal Interval Design (BOIN) trial design will be used to determine the maximum tolerated dose of oral NAC. Our secondary objective is to assess palatability of the oral NAC formulation by comparing facial expressions when taking oral NAC versus other medications commonly given to cholestatic infants. conditions: Biliary Atresia studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The study consists of two parts:
|
* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.
|
* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. primaryPurpose: OTHER masking: NONE maskingDescription: N/A. No Masking count: 12 type: ESTIMATED name: N-Acetylcysteine measure: No emesis within 30 minutes of administration of at least 3 of 4 total doses of oral NAC measure: Oral NAC palatability compared to clinically indicated medications using the facial expression scale measure: Oral NAC-specific adverse event evaluation sex: ALL minimumAge: 122 Days maximumAge: 273 Days stdAges: CHILD hasResults: False
|
<|newrecord|> nctId: NCT06260553 id: SCOG008 briefTitle: Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC overallStatus: ENROLLING_BY_INVITATION date: 2024-02-07 date: 2025-02-07 date: 2025-08-07 date: 2024-02-15 date: 2024-02-15 name: Fujian Cancer Hospital class: OTHER_GOV briefSummary: To evaluate the efficacy of metronomic chemotherapy combination with tislelizumab in EGFR/ALK-negative advanced NSCLC patients intolerant to first-line standard chemotherapy. conditions: EGFR/ ALK-negative Advanced NSCLC studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: tislelizumab and metronomic oral vinorelbine measure: PFS measure: ORR measure: DCR measure: AE sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian cancer hospital city: Fuzhou state: Fujian country: China lat: 26.06139 lon: 119.30611 hasResults: False
|
<|newrecord|> nctId: NCT06260540 id: Core Endurance briefTitle: Core Endurance in Healthy Young Adults overallStatus: RECRUITING date: 2024-02-01 date: 2024-02-29 date: 2024-04-29 date: 2024-02-15 date: 2024-03-26 name: Karabuk University class: OTHER briefSummary: This study aimed to examine the effect of core endurance levels on upper extremity function, muscle strength and reaction time in healthy young adults. The "core" region functions as a connection point between the upper and lower extremities and enables the transfer of force from this region to the extremities. This region is a basic structure where the force required for all movements is generated and transmitted from the proximal segments to the distal segments. "Core" stabilization has a significant impact on limb functionality, and stabilization of the proximal segments is necessary to maintain the mobility and function of the distal segments. To establish a stable base during functional activities, the "core" muscles are activated before the upper and lower extremity muscles. This ensures force production and transfer of resulting forces, thus supporting the mobility of the distal segments. Increasing core stabilization increases force production in the extremities, and control of core strength, balance and movement maximizes upper and lower extremity functions. Any impairment in core stabilization reduces the quality of movement and increases the risk of injury to the upper extremity. Therefore, it has been stated that "core" stabilization has a significant effect on athletic performance and upper extremity functions. There are not enough studies in the literature investigating this effect in healthy young adults. Most existing studies focus on the role of core endurance on athlete performance.
|
The aim of this study is not only to investigate core endurance levels in healthy young adults but also to examine the effect of core endurance levels on upper extremity function, muscle strength and reaction time. conditions: Health Risk Behaviors studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: CROSS_SECTIONAL count: 104 type: ESTIMATED measure: Side bridge test measure: Prone bridge test (plank) test measure: Trunk flexion endurance test measure: Sorensen test measure: Purdue Pegboard test measure: Isometric hand dynamometer for muscle strength measure: Nelson hand reaction test sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Karabuk University status: RECRUITING city: Karabuk zip: 78000 country: Turkey lat: 41.20488 lon: 32.62768 hasResults: False
|
<|newrecord|> nctId: NCT06260527 id: ARTS-011-101 briefTitle: Safety and Pharmacokinetic Study of ARTS-011 in Chinese Healthy Volunteers overallStatus: RECRUITING date: 2023-08-30 date: 2024-05-30 date: 2024-09-30 date: 2024-02-15 date: 2024-02-15 name: Allorion Therapeutics Inc class: INDUSTRY briefSummary: This single- and multiple-ascending dose study is a Phase 1, first in human study of ARTS-011. The goal of the study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of ARTS-011 after single and multiple oral doses of ARTS-011 in Chinese healthy volunteers. conditions: Chinese Healthy Volunteer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Single ascending dose (SAD) following by multiple ascending dose (MAD) and food effect study primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 76 type: ESTIMATED name: ARTS-011 name: Placebo measure: Incidence of Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs measure: Number of Adverse Events (AEs) according to severity measure: Number of participants with change from baseline in vital signs (blood pressure, pulse rate, oral temperature) measure: Number of participants with change from baseline in 12-Lead Parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) measure: Number of participants with change from baseline physical examination measure: Incidence and magnitude of treatment emergent clinical laboratory abnormalities measure: Number of participants with change in 24-hour creatine clearance from baseline measure: Maximum Observed Plasma Concentration (Cmax) of ARTS-011 in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) measure: Time to Reach Maximum Observed Plasma Concentration (Tmax) of ARTS-011 in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) measure: Dose Normalized Maximum Observed Plasma Concentration (Cmax[dn]) of ARTS-011 in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) measure: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) of ARTS-011 in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) measure: Plasma Decay Half-Life (t1/2) of ARTS-011 in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) measure: Apparent Volume of Distribution (Vz/F) of ARTS-011 in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) measure: Apparent Clearance (CL/F) of ARTS-011 in Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) if data permit measure: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) of ARTS-011 in Single Ascending Dose (SAD) measure: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of ARTS-011 in Multiple Ascending Dose (MAD) measure: Dose Normalized Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf[dn]) of ARTS-011 in Single Ascending Dose (SAD) measure: Dose Normalized Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau[dn]) of ARTS-011 in Multiple Ascending Dose (MAD) measure: Maximum Observed Plasma Concentration (Cmax) of ARTS-011 in Food Effect Cohort measure: Time to Reach Maximum Observed Plasma Concentration (Tmax) of ARTS-011 in Food Effect Cohort measure: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) of ARTS-011 in Food Effect Cohort measure: Plasma Decay Half-Life (t1/2) of ARTS-011 in Food Effect Cohort measure: Apparent Clearance (CL/F) of ARTS-011 in Food Effect Cohort if data permit measure: Apparent Volume of Distribution (Vz/F) of ARTS-011 in Food Effect Cohort if data permit sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Beijing Friendship Hospital, Capital Medical University status: RECRUITING city: Beijing state: Beijing zip: 100050 country: China name: Ruihua Dong, MD role: CONTACT phone: 010-80839386 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False
|
<|newrecord|> nctId: NCT06260514 id: APR-1051-001 briefTitle: Study of APR-1051 in Patients With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2027-06 date: 2028-06 date: 2024-02-15 date: 2024-02-15 name: Aprea Therapeutics class: INDUSTRY briefSummary: The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors. conditions: Advanced Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 79 type: ESTIMATED name: APR-1051 measure: Treatment-related adverse events measure: Recommended dose of APR-1051 measure: Pharmacokinetics: Cmax/Cmin of APR-1051 measure: Pharmacokinetics: Tmax of APR-1051 measure: Pharmacokinetics: AUC of APR-1051 measure: Pharmacokinetics: t1/2 of APR-1051 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06260501 id: ATADEK-2023-13/463 briefTitle: Wetting Solution-ideal Body Weight Ratio in Liposuction Procedures overallStatus: COMPLETED date: 2021-09-01 date: 2023-09-30 date: 2023-10-30 date: 2024-02-15 date: 2024-02-15 name: Acibadem University class: OTHER briefSummary: Although the use of wetting solutions during high-volume liposuction is a standard approach, it is unclear how to optimize wetting solutions and components and their effect on postoperative complications.. Since the super-wet technique (aspiration of 1 cc per 1 cc of infiltrate) was introduced in 1986, it has become one of the most frequently applied techniques worldwide . Adrenaline and lidocaine are often added to WS due to their hemostatic and analgesic effects One of the major advantages of super-wet technique is that blood loss is quite low. However, potential cardiovascular side effects of WS and the amounts of epinephrine and lidocaine they contain, such as volume overload, local anesthetic toxicity, hypertension, arrhythmia, and tachycardia, are still a scoop of investigation. In this study, we examined the WS and the medications it contains from a different perspective to understand the possible cause of these adverse outcomes. Despite the most suitable candidates for liposuction are patients with a BMI\<30 kg/m2 and low comorbidity and age, the patient group undergoing liposuction is often obese, and overweight individuals require that obesity-related pathophysiological changes be taken into consideration. Therefore, we analyzed the patients by dividing them into two groups according to the amount of WS applied according to their IBW (WS/IBW≤90ml/kg: group I and WS/IBW\>90ml/kg: group I). In this study we aimed to evaluate the effect of wetting solutions and components calculated according to ideal body weight (IBW) on postoperative complications conditions: Liposuction conditions: Obesity conditions: Postoperative Complications studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 192 type: ACTUAL name: super-wet technique measure: Mean arterial pressure (MAP) was measured to detect hypertension and hypotension. measure: The Numerical Pain Rating Scale (NRS) was used to assess postoperative pain level sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Acibadem Altunizade Hospital city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
|
<|newrecord|> nctId: NCT06260488 id: 8925 briefTitle: Histological Segmentation of the Superficial Femoral Artery From Microscan to CT Using Artificial Intelligence acronym: CTPred overallStatus: NOT_YET_RECRUITING date: 2024-02-15 date: 2025-06-15 date: 2025-08-15 date: 2024-02-15 date: 2024-02-15 name: University Hospital, Strasbourg, France class: OTHER briefSummary: The femoropopliteal artery segment (FPAS) is one of the longest arteries in the human body, undergoing torsion, compression, flexion and extension due to lower limb movements. Endovascular surgery is considered to be the treatment of choice for the peripheral arterial disease, the results of which depend on the physiological forces on the arterial wall, the anatomy of the vessels and the characteristics of the lesions being treated. The atheromatous disease includes, in a simple way, 3 categories of plaques: calcified, fibrous, and lipidic. The study of these plaques and their differentiation in imaging and histology in the FPAS has already been the subject of research. To treat them, there are angioplasty balloons and stents with different designs and components, with different mechanical properties and different impregnated molecules.
|
There is no non-invasive method (imaging) to accurately differentiate lesions along the FPAS. The analysis is performed from the preoperative CT scan, but there are high-resolution scanners that allow a quasi-histological analysis of the tissue.
|
This microscanner can be used ex vivo. In the framework of a project, the learning algorithm was be créated (Convolutional Neural Networks) to automatically segment microscanner slices: after taking FPAS from amputated limbs, we correlated ex-vivo microscanner images of the arteries with their histology. The correlation was then performed manually between the microscanner images, and the histological sections obtained. the algorithm well be trained on these slices and validated its performance. The validation of the CT and microscanner concordance was the subject of scientific publications. conditions: Peripheral Artery Disease conditions: Femoropopliteal Stenosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 20 type: ESTIMATED name: Endovascular surgery measure: Assessing the feasibility of histological segmentation of the superficial femoral artery on preoperative microscanner using artificial intelligence sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06260475 id: IUA - 246-18 briefTitle: IUA Committee Research Project on the Management of TASC C and D Aortoiliac Lesions overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-08-31 date: 2024-12-31 date: 2024-02-15 date: 2024-02-15 name: Universidade do Porto class: OTHER name: Clinical Centre of Serbia name: University of Padova name: University of Bari name: University of Trieste name: University of Nis name: Centro Hospitalar de Vila Nova de Gaia/Espinho name: Hospital Centre Hospitalar de Trás-os-Montes e Alto Douro name: Centro Hospitalar do Porto briefSummary: This study aims to evaluate the clinical, imaging results of endovascular revascularization of the aorto-iliac sector in comparison with aortobifemoral bypass and the hybrid approach, in patients with atherosclerotic disease of the iliac sector classified as type C and D by the TransAtlantic Inter-Society Consensus (TASC II conditions: Aortoiliac Atherosclerosis conditions: Aortoiliac Occlusive Disease conditions: Aortoiliac Atherosclerosis With Gangrene conditions: Aortoiliac Atherosclerosis Without Gangrene conditions: Aortoiliac Obstruction conditions: Peripheral Arterial Disease conditions: Peripheral Vascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 500 type: ESTIMATED name: Aortobifemoral bypass name: aortoiliac stenting measure: Major Amputation measure: Cardiovascular Death measure: acute myorcardial infartion measure: Major Adverse Limb Events measure: Major adverse cardiovascular events measure: Death measure: Intensive care unit instay measure: acute kidney injury (AKI) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centro Hospitalar Universitário de São João, EPE city: Porto zip: 4200-319 country: Portugal name: Joao Rocha-Neves role: CONTACT phone: +351910486230 email: [email protected] lat: 41.14961 lon: -8.61099 facility: Faculdade de Medicina da Universidade do Porto city: Porto zip: 4200-319 country: Portugal lat: 41.14961 lon: -8.61099 hasResults: False
|
<|newrecord|> nctId: NCT06260462 id: 10 years adrenal insufficiency briefTitle: Effects of Steroid Replacement Therapy on Metabolic, Cardiovascular and Bone Outcomes in Adrenal Insufficiency overallStatus: COMPLETED date: 2012-01-01 date: 2022-09-30 date: 2023-12-30 date: 2024-02-15 date: 2024-02-15 name: University of Palermo class: OTHER briefSummary: The current study is a randomized, open study aimed to compare the effects of conventional glucocorticoid replacement treatment and dual-release hydrocortisone on anthropometric, metabolic, cardiovascular and bone outcomes in treatment-naïve patients with primary adrenal insufficiency and secondary adrenal insufficiency in a 10 year-observation period. conditions: Adrenal Insufficiency studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 88 type: ACTUAL name: dual-release hydrocortisone name: Conventional glucocortidois measure: Change of body weight measure: Change of anthropometric parameters measure: Change of metabolic parameters measure: Change of insulin sensitivity parameters measure: Change of cardiovascular parameters measure: Change of bone metabolic parameters measure: Change of bone density measure: Change of vascular parameters sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
|
<|newrecord|> nctId: NCT06260449 id: Trematode briefTitle: Different Treatment Approaches of Presumed Trematode-Induced Uveitis overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-21 date: 2024-10-21 date: 2024-12-21 date: 2024-02-15 date: 2024-02-15 name: Assiut University class: OTHER briefSummary: Different Treatment Approaches of Presumed Trematode-Induced Uveitis including periocular injection and medical treatment Nd laser treatment conditions: Uveitis studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Single group tested by intervention and medical treatment primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 31 type: ESTIMATED name: Surgical removal measure: Surgical removal sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Assiut city: Assiut country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
|
<|newrecord|> nctId: NCT06260436 id: Tharwat gamal Mohamed briefTitle: Questionnaire of Lower Urinary Tract Symptoms Among Women Before and After Surgical Correction of Uterine Prolapse overallStatus: RECRUITING date: 2021-05-30 date: 2024-09-30 date: 2024-12-30 date: 2024-02-15 date: 2024-02-21 name: Assiut University class: OTHER briefSummary: . The study will include patients who underwent Pelvic reconstructive surgery for advanced pelvic organ prolapse (POP-Q ≥ 3). Data regarding preoperative evaluation, surgical procedure, and post-operative management will be collected. women will receive a follow up questionnaire. . The baseline questionnaire included data on age, urinary incontinence, daytime frequency, nocturia, postmicturition dribble, straining, urgency, incomplete bladder emptying, and hesitancy. Women were asked about leakage caused by coughing or sneezing, moving, lifting, sleeping, sexual intercourse, urgency, and rest. conditions: Pelvic Organ Prolapse studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 180 type: ESTIMATED measure: effect of surgical correction of pelvic organ prolapse on the lower urinary tract symptoms measure: effect of surgical correction of pelvic organ prolapse on the quality of life sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Assuit University status: RECRUITING city: Assiut state: Assuit zip: 2063045 country: Egypt name: tharwat gl mohamed role: CONTACT phone: 01151166826 email: [email protected] name: tht tg mohamed role: CONTACT phone: 01017941889 email: [email protected] name: abdelghaffar m mohamed, professor role: PRINCIPAL_INVESTIGATOR lat: 27.18096 lon: 31.18368 hasResults: False
|
<|newrecord|> nctId: NCT06260423 id: 18/1/2024 briefTitle: The Effect of Clinical Experience on the Quality of Obturation and Periapical Changes of Teeth Treated With Matched Cones in Combination With Bioceramic Sealer overallStatus: RECRUITING date: 2023-01-01 date: 2025-02-01 date: 2025-04-01 date: 2024-02-15 date: 2024-02-15 name: Al-Azhar University class: OTHER briefSummary: Evaluation of the impact of clinical experience on the quality of obturation and periapical changes of clinical cases using lateral compaction with bioceramic sealers and matched cone obturation with bioceramic sealers both clinically and radiographically. conditions: Obturation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Experienced dentist using lateral compaction with bioceramic sealer. name: Unexperienced dentist using lateral compaction with bioceramic sealer. name: Experienced dentist using Single cone with bioceramic sealer. name: Unexperienced dentist using Single cone with bioceramic sealer. measure: Postoperative pain assessment measure: Postoperative pain assessment measure: Postoperative pain assessment measure: Postoperative pain assessment measure: Postoperative pain assessment measure: The quality of obturation and the voids within the root canal filling sex: ALL minimumAge: 20 Years maximumAge: 40 Years stdAges: ADULT facility: Al-Azhar university status: RECRUITING city: Cairo zip: 11651 country: Egypt name: Mohamed Badr, Master role: CONTACT phone: 0201111777739 email: [email protected] lat: 30.06263 lon: 31.24967 hasResults: False
|
<|newrecord|> nctId: NCT06260410 id: 10512 id: NL84672.078.23 type: OTHER domain: CCMO briefTitle: Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics acronym: LUTRAC overallStatus: RECRUITING date: 2024-02-20 date: 2027-02-01 date: 2027-02-01 date: 2024-02-15 date: 2024-04-22 name: Erasmus Medical Center class: OTHER briefSummary: This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment. conditions: Prostate Cancer Metastatic studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Blood draw for ctDNA and circulating tumor cell collection. measure: Overall survival measure: Progression free survival measure: Heterogeneity of PSMA-positivity measure: Effect of CTC PSMA expression on response to treatment. measure: Effect of biomarkers in blood on response to treatment. measure: PSMA-PET scan data and response to treatment. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus MC status: RECRUITING city: Rotterdam state: Zuid-Holland zip: 3015 CN country: Netherlands name: Stijn Koolen, PhD role: CONTACT phone: +31638740656 email: [email protected] lat: 51.9225 lon: 4.47917 hasResults: False
|
<|newrecord|> nctId: NCT06260397 id: analgesia for MRM surgeries briefTitle: Serratus Anterior Plane Block and Costotransverse Block for Analgesia Following Modified Radical Mastectomy Surgeries overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2025-02-28 date: 2025-03-30 date: 2024-02-15 date: 2024-02-26 name: Ain Shams University class: OTHER briefSummary: Adequate pain management following modified radical mastectomy (MRM) is crucial for early ambulation and patient satisfaction. Breast cancer is the most common malignancy in females, with an increasing incidence in recent years. Surgery is one of the mainstays of therapy for breast cancer, and modified radical mastectomy (MRM) is the most effective and common type of invasive surgical treatment. Post-mastectomy pain syndrome (PMPS) is a surgical complication of breast surgery characterized by chronic neuropathic pain. The aim of this study is to investigate the efficacy and safety of single injection CTB versus SAPB on post-operative acute pain as a part of a multimodal analgesia plan in patients undergoing MRM. conditions: Regional Anesthesia Morbidity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: serratus anterior plane block name: costotransverse block name: patient controlled analgesia measure: Visual Analogue Scale score at 0,6,12 and 24 hour post-operatively. visual analogue scale is a scale from 0 to 10, 0 represent no pain at all and 10 represent the worst pain measure: The total dose of nalbuphine consumption is used postoperatively per patient rescue analgesia for 24. sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
|
<|newrecord|> nctId: NCT06260384 id: FMASU R 139/2022 briefTitle: Wolf-Parkinson-White Syndrome and Asymptomatic Pre-excitation in Africa (a Multicenter WPW African Registry) overallStatus: RECRUITING date: 2022-05-01 date: 2024-05-31 date: 2024-10-31 date: 2024-02-15 date: 2024-02-26 name: Ain Shams University class: OTHER briefSummary: The purpose of this prospective observational study is to characterize the clinical profile of patients with WPW syndrome and patients with asymptomatic WPW pattern on ECG in different African countries and how these patients are managed across Africa Participants would include many different ethnicities at centers where the number of cardiac patients treated is high. All patients attending outpatient cardiology clinics or referred to Cath Lab for electrophysiological studies who are diagnosed to have a Wolf-Parkinson white pattern on the ECG are either symptomatic or asymptomatic. All patients fulfilling the eligibility criteria will be approached by the research team and asked if they wish to take part in the study.
|
The exclusion criteria will be any participant who does not consent to the study.
|
A baseline cardiovascular history (including hypertension, diabetes, heart failure, coronary artery disease, hyperlipidemia, smoking, valve disease, and arrhythmia) will be recorded.
|
A detailed history will be taken about symptoms, medications and presence of family history of similar cases or sudden cardiac death 12-lead ECG will be recorded to confirm the presence of pre-excitation and determine the localization of the accessory pathway using the modified Aruda algorithm. This will be done by two of the research teams in each center.
|
Then other data from the electrophysiological study and ablation will be filled in by the research team from the data systems of each center. conditions: Wolf Parkinson White Syndrome conditions: Arrythmias studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: electrocardiogram measure: No recurrence of symptoms measure: Assessment of performance outcome of each center sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Ain shams university status: RECRUITING city: Cairo state: Outside US zip: 11851 country: Egypt name: Nabil M Farag, MD role: CONTACT phone: +201223102180 email: [email protected] role: CONTACT email: [email protected] name: lamyaa E Allam, MD role: PRINCIPAL_INVESTIGATOR lat: 30.06263 lon: 31.24967 hasResults: False
|
<|newrecord|> nctId: NCT06260371 id: ORIGAMI briefTitle: National Observatory of Mycoplasma Infections in Children Under 18 Ages in France acronym: ORIGAMI overallStatus: RECRUITING date: 2023-09-01 date: 2030-09-01 date: 2030-09-01 date: 2024-02-15 date: 2024-02-15 name: Association Clinique Thérapeutique Infantile du val de Marne class: OTHER name: GPIP briefSummary: This study was set up because of an unusual increase in the number of cases of mycoplasma infections in France between June and November 2023.
|
Clinical data from children with mycoplasma infections will be collected to characterise this infection and facilitate hospital management. conditions: Mycoplasma Infections conditions: Hospitalized Children studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 3000 type: ESTIMATED measure: Number of patients hospitalized for mycoplasma infections measure: medical characterisation of mycoplasma infections measure: Identify risk factors of serious infection measure: Identify predictive signs of serious infection measure: Type of complications measure: Patients outcome measure: healthcare used for infected children measure: treatment used during hospitalisation measure: clinical description of infected children measure: Type of mycoplasma involved in infected children measure: performance of complementary diagnostic tests for lung disorders measure: compare medical data collected during hospitalisation sex: ALL minimumAge: 1 Day maximumAge: 17 Years stdAges: CHILD facility: ACTIV status: RECRUITING city: Créteil zip: 94600 country: France name: Corinne Levy, MD role: CONTACT phone: 1 48 85 04 04 phoneExt: +33 email: [email protected] name: Stéphane Béchet, MSc role: CONTACT phone: 1 48 85 04 04 phoneExt: +33 email: [email protected] lat: 48.78333 lon: 2.46667 hasResults: False
|
<|newrecord|> nctId: NCT06260358 id: 6043 briefTitle: Multidisciplinary Assesssment of Structured Report for Cervical Cancer Staging acronym: STRECC overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2025-03-31 date: 2024-02-15 date: 2024-02-15 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: This study aims to validate a structured report for cervical cancer anchored to the FIGO staging system. A structured report is hypothesized to aid in uniformly applying FIGO staging, reducing staging discrepancies and improving patient care and outcomes.
|
Furthermore, we believe that the participation of the clinicians will improve the quality of the report to minimize the need for multidisciplinary team discussion conditions: Cervical Cancer studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Survey measure: Efficacy of a contextual structured report measure: Difference between satisfaction rate with narrative and structured report; measure: Comparison Single items response rate (for items 6 to 12 of the questionnaire related to clinical information), on both narrative and structured reports; measure: Differences in the single 6-to-12 items response rate between structured and narrative reports. sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Advanced Radiology Center status: RECRUITING city: Rome zip: 00168 country: Italy name: Luca Russo role: CONTACT phone: +390630158637 email: [email protected] lat: 41.89193 lon: 12.51133 hasResults: False
|
<|newrecord|> nctId: NCT06260345 id: CAPRICE briefTitle: CommunautAry Pediatric bacteRial Infection in Intensive CarE Unit acronym: CAPRICE overallStatus: RECRUITING date: 2024-01-01 date: 2030-01-01 date: 2030-01-01 date: 2024-02-15 date: 2024-02-15 name: Association Clinique Thérapeutique Infantile du val de Marne class: OTHER name: GFRUP (Groupe Francophone de Réanimation et d'Urgences Pédiatrique) name: GPIP : Groupe de Pathologies Infectieuses Pédiatriques name: Centre National de Référence des Streptocoques name: Centre National de Référence des Pneumocoques name: Centre National de Référence des Méningocoques et Haemophilus influenzae name: Centre National de Référence des staphylocoques name: Centre National de Référence des E. Coli briefSummary: Severe bacterial infections are a worldwide scourge. However, the epidemiology of this type of infection varies over time. It is therefore essential to monitor them in order to prevent them more effectively. At this time, in France, no monitoring exists for this kind of infections. conditions: Hospitalized Children conditions: Severe Infection conditions: Invasive Bacterial Infection studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 3000 type: ESTIMATED measure: number of pediatrics cases of severe communautary bacterial infections measure: medical characterisation of children hospitalized for severe communautary bacterial infection case measure: Identify risk factors of serious infection measure: Identify predictive signs of severe cases in infected children. measure: healthcare used for infected children measure: Type of complications measure: Patients outcome measure: treatment used during hospitalisation measure: Bacterial strain characterization sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Association Clinique Thérapeutique Infantile du val de Marne status: RECRUITING city: Créteil zip: 94600 country: France name: Corinne Levy, MD role: CONTACT phone: 1 48 85 04 04 phoneExt: +33 email: [email protected] name: Stéphane Béchet, MsC role: CONTACT phone: 1 48 85 04 04 phoneExt: +33 email: [email protected] lat: 48.78333 lon: 2.46667 hasResults: False
|
<|newrecord|> nctId: NCT06260332 id: INST UNM 2302 id: 23-293 type: OTHER domain: UNM HSC IRB briefTitle: Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors overallStatus: RECRUITING date: 2023-10-20 date: 2024-08-30 date: 2024-12-31 date: 2024-02-15 date: 2024-02-15 name: New Mexico Cancer Care Alliance class: OTHER name: University of New Mexico briefSummary: This clinical trial tests whether increased activity throughout the day can improve the chronic pain and associated symptoms that breast cancer survivors may experience after surgery. Staying active is a key factor of one's physical, mental, and social health and well-being. Moving more could also reduce pain and associated stress, anxiety, or depression. Using a fitness tracker may help patients to move around more, whether or not they choose to exercise. Information gathered from this study may help researchers learn how the use of a Fitbit tracker with health coaching may improve physical activity and reduce pain in young, Hispanic breast cancer survivors. conditions: Breast Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 25 type: ESTIMATED name: Supportive Care (Fitbit) measure: Recruitment rate (Feasibility) measure: Retention rate (Feasibility) measure: Adherence rate (Feasibility) measure: Incidence of adverse events measure: Change in chronic post-surgical pain measure: Change in physical activity measure: Change in health-related quality of life (hrQOL) sex: FEMALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: University of New Mexico Comprehensive Cancer Center status: RECRUITING city: Albuquerque state: New Mexico zip: 87106 country: United States name: Ellen R Wojcik, MBA-HCM role: CONTACT email: [email protected] name: Cheryl A Sampson, MBA role: CONTACT email: [email protected] name: Jacklyn M Nemunaitis, MD role: PRINCIPAL_INVESTIGATOR name: Cindy K Blair, Ph.D. role: SUB_INVESTIGATOR lat: 35.08449 lon: -106.65114 hasResults: False
|
<|newrecord|> nctId: NCT06260319 id: C19-64 briefTitle: Decoding Developmental Disorders in Humams acronym: devodecode overallStatus: COMPLETED date: 2019-01-01 date: 2024-01-01 date: 2024-01-01 date: 2024-02-15 date: 2024-02-15 name: Institut National de la Santé Et de la Recherche Médicale, France class: OTHER_GOV name: Imagine Institute name: Commissariat A L'energie Atomique briefSummary: The DEVO-DECODE project aims to align our currently limited knowledge currently limited knowledge of the genetic architecture of developmental with our more advanced knowledge of their "phenome".
|
To this end, we aim to establish a homogeneous cohort of patients with with developmental disorders to identify new genetic variants genetic variants, and thus study the association between developmental and genetic variants. Secondary objectives are:2
|
* Carry out WGS studies not only to refine exosomal sequencing data exome sequencing data, but above all to identify and validate non-coding non-coding DNA alterations, in both transcribed and non-transcribed transcribed or non-transcribed genomic domains
|
* Develop precise preclinical models for functional studies of pathophysiological pathways conditions: Genetic Diseases studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 720 type: ACTUAL name: Whole genome sequencing and Genome-Epigenome-Phenome Associations measure: Primary objectives measure: secondary objectives 1 measure: secondary objectives 2 sex: ALL minimumAge: 1 Year maximumAge: 90 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Institut Imagine city: Paris zip: 75015 country: France lat: 48.85341 lon: 2.3488 hasResults: False
|
<|newrecord|> nctId: NCT06260306 id: STUDY00002568 briefTitle: Hip Activation vs. Hip Activation + Core Stabilization overallStatus: COMPLETED date: 2024-01-24 date: 2024-04-12 date: 2024-04-12 date: 2024-02-15 date: 2024-04-26 name: Louisiana State University Health Sciences Center Shreveport class: OTHER briefSummary: The purpose of this investigation is to compare the effects of a combined hip activation and core stabilization training home exercise program (HEP) versus a hip activation training HEP alone on lower extremity (LE) frontal plane mechanics in healthy individuals.
|
Specific Aim 1: To determine whether between- and/or within-group differences exist on the Forward Step-Down test (FSDT) when comparing a combined hip activation and core stabilization training HEP as compared to a hip activation training HEP.
|
Specific Aim 2: To determine whether between- and/or within-group differences exist on the peak external knee abduction moment when comparing a combined hip activation and core stabilization training HEP to a hip activation training HEP.
|
Specific Aim 3: To determine whether between- and/or within-group differences exist on gluteal and core muscle surface electromyography (sEMG) when comparing a combined hip activation and core stabilization training HEP to a hip activation training HEP.
|
Specific Aim 4: To determine whether a dose-response relationship exists between HEP compliance and change on the FSDT, peak external knee abduction moment, and sEMG. conditions: Movement, Abnormal conditions: Lower Extremity Problem studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The PI who will be performing the data analysis will be blinded to participants' random group allocation. The other investigators who will be collecting the outcome data will know the group allocation. whoMasked: INVESTIGATOR count: 34 type: ACTUAL name: Hip activation home exercise program name: Hip activation plus core stabilization home exercise program measure: Forward Step Down Test (FSDT) measure: Maximal volitional isometric contraction (MVIC) via sensory electromyography (sEMG) of gluteus maximus (GMax) measure: Mean activation of GMax via sEMG measure: Peak activation of GMax via sEMG measure: MVIC via sEMG of gluteus medius (GMed) measure: Mean activation of GMed via sEMG measure: Peak activation of GMed via sEMG measure: MVIC via of transversus abdominis (TA) measure: Mean activation of TA via sEMG measure: Peak activation of TA via sEMG measure: Peak external knee abduction moment during drop landing task measure: Compliance with Home Exercise Program sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: LSU Health Sciences Center at Shreveport city: Shreveport state: Louisiana zip: 71103 country: United States lat: 32.52515 lon: -93.75018 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-12-07 uploadDate: 2024-01-18T21:23 filename: Prot_SAP_000.pdf size: 292995 hasResults: False
|
<|newrecord|> nctId: NCT06260293 id: 4-2022-0208 briefTitle: The Effect of Post-operative Exercise in Gastric Cancer Patients: A Randomized Controlled Trial (RCT) Study overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-03 date: 2024-04-30 date: 2024-04-30 date: 2024-02-15 date: 2024-02-15 name: Yonsei University class: OTHER briefSummary: Medical advancements are enhancing the survival rates of individuals with gastric cancer. The growing population of gastric cancer survivors underscores the importance of managing treatment-related after-effects and side effects. Diminished physical function in cancer patients, particularly following gastric cancer surgery, is linked to increased mortality. The substantial decline in physical activity post-surgery contributes to a notable reduction in cardiorespiratory fitness and lower extremity muscle strength. Early postoperative exercise has demonstrated positive outcomes in colorectal cancer patients, facilitating early hospital discharge and supporting long-term recovery. However, there is a paucity of research on the efficacy of early postoperative exercise in the context of gastric cancer. Therefore, this study aims to evaluate the impact of early postoperative exercise on physical function following gastric cancer surgery. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 52 type: ACTUAL name: exercise measure: Shorts Physical Performance Battery(SPPB) sex: ALL minimumAge: 19 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Surgery, Yonsei University College of Medicine city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
|
<|newrecord|> nctId: NCT06260280 id: 4 briefTitle: Chronic Sleep Deprivation and Changes in Cortical and Hippocampal Volume overallStatus: NOT_YET_RECRUITING date: 2024-02-26 date: 2024-05-26 date: 2024-06-01 date: 2024-02-15 date: 2024-02-15 name: Instituto Mexicano del Seguro Social class: OTHER_GOV briefSummary: Sleep is a physiological state that is essential for human performance, including academic, occupational, interpersonal, and psychological aspects. Sleep disruption or deprivation leads to a loss of psychomotor skills and an increased association with various diseases. Therefore, it is critical to assess how chronic sleep deprivation affects medical residents who work long shifts, including those assigned during their training. conditions: Sleep Deprivation conditions: Hippocampal Atrophy conditions: Cortical Irregularity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 37 type: ESTIMATED name: Cerebral Nuclear Magnetic Resonance measure: Change in Hippocampal volumetry. measure: Change in cortical volumetry sex: ALL minimumAge: 24 Years maximumAge: 30 Years stdAges: ADULT facility: Unidad Medica de Alta Especialidad No. 1, Bajío city: Leon state: Guanajuato zip: 37260, country: Mexico lat: 21.12908 lon: -101.67374 hasResults: False
|
<|newrecord|> nctId: NCT06260267 id: 000417 briefTitle: A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis overallStatus: RECRUITING date: 2024-03-12 date: 2025-09-15 date: 2025-09-15 date: 2024-02-15 date: 2024-04-05 name: Ferring Pharmaceuticals class: INDUSTRY briefSummary: To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC). conditions: Ulcerative Colitis studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 90 type: ESTIMATED name: Microbiota suspension name: Microbiota capsule name: Placebo suspension name: Placebo capsule measure: Treatment-emergent adverse events from baseline to week 52 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ferring Investigational Site status: RECRUITING city: North Little Rock state: Arkansas zip: 72117 country: United States name: Global Clinical Compliance role: CONTACT lat: 34.76954 lon: -92.26709 facility: Ferring Investigational Site status: RECRUITING city: Jacksonville state: Florida zip: 32256 country: United States name: Global Clinical Compliance role: CONTACT lat: 30.33218 lon: -81.65565 facility: Ferring Investigational Site status: RECRUITING city: Oklahoma City state: Oklahoma zip: 73102 country: United States name: Global Clinical Compliance role: CONTACT lat: 35.46756 lon: -97.51643 hasResults: False
|
<|newrecord|> nctId: NCT06260254 id: 244826201 briefTitle: Effects of Railway Vibration on Sleep and Disease acronym: BioVib overallStatus: RECRUITING date: 2024-02-05 date: 2024-06-30 date: 2024-12-31 date: 2024-02-15 date: 2024-02-21 name: Göteborg University class: OTHER name: University of Pennsylvania name: University of Manitoba briefSummary: This study will investigate the biological mechanisms linking sleep disruption by vibration and noise, and the development of cardiometabolic disease. In a laboratory sleep study, the investigators will play railway vibration of different levels during the night. The investigators will also measure objective sleep quality and quantity, cognitive performance across multiple domains, self-reported sleep and wellbeing outcomes, and blood samples. Blood samples will be analyzed to identify metabolic changes and indicators of diabetes risk in different nights. Identifying biomarkers that are impacted by sleep fragmentation will establish the currently unclear pathways by which railway vibration exposure at night can lead to the development of diseases in the long term, especially metabolic disorders including diabetes. conditions: Noise Exposure conditions: Sleep Disturbance conditions: Sleep Hygiene conditions: Metabolic Disturbance conditions: Cognitive Change conditions: Glucose Metabolism Disorders (Including Diabetes Mellitus) conditions: Vibration; Exposure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: All participants will be exposed to each of the different vibration conditions. Each study night is treated as a separate arm of the crossover study. The order of the vibration exposure conditions will be be randomly assigned across participants using a Latin square design to avoid first-order carryover effects. Each subject will be exposed to one night of each of the following:
|
Quiet night: No noise or vibration will be played, serving as a control night to assess individual baseline sleep, metabolic profile, and cognitive performance; Three railway vibration nights to determine consequences of noise-disrupted sleep. The vibration level in these three nights will be 0.5 mm/s, 0.7 mm/s and 0.9 mm/s respectively, so that exposure-response relationships can be derived. primaryPurpose: BASIC_SCIENCE masking: DOUBLE maskingDescription: Participants will be aware that in any given study night they can be exposed to railway vibration and noise. They will not be informed what exposure condition will occur in any given night, but they can become unblinded to the exposure if they are awake, as they will may hear the noise or feel the vibration.
|
Study investigators responsible for analysing cognitive performance variables and physiological sleep data will be be blind to which vibration and noise interventions were introduced on which study nights. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 24 type: ESTIMATED name: Railway noise name: Low level railway vibration name: Intermediate level railway vibration name: High level railway vibration measure: Fasting insulin resistance in the morning immediately after the Control night measure: Fasting insulin resistance in the morning immediately after the low vibration night measure: Fasting insulin resistance in the morning immediately after the intermediate vibration night measure: Fasting insulin resistance in the morning immediately after the high vibration night measure: Total sleep time during the Control night measure: Total sleep time during the low vibration night measure: Total sleep time during the intermediate vibration night measure: Total sleep time during the high vibration night measure: Total amount of N1 sleep during the Control night measure: Total amount of N2 sleep during the Control night measure: Total amount of N3 sleep during the Control night measure: Total amount of rapid eye movement (REM) sleep during the Control night measure: Total amount of N1 sleep during the low vibration night measure: Total amount of N2 sleep during the low vibration night measure: Total amount of N3 sleep during the low vibration night measure: Total amount of rapid eye movement (REM) sleep during the low vibration night measure: Total amount of N1 sleep during the intermediate vibration night measure: Total amount of N2 sleep during the intermediate vibration night measure: Total amount of N3 sleep during the intermediate vibration night measure: Total amount of rapid eye movement (REM) sleep during the intermediate vibration night measure: Total amount of N1 sleep during the high vibration night measure: Total amount of N2 sleep during the high vibration night measure: Total amount of N3 sleep during the high vibration night measure: Total amount of rapid eye movement (REM) sleep during the high vibration night measure: Wakefulness after sleep onset (WASO) during the Control night measure: Wakefulness after sleep onset (WASO) during the low vibration night measure: Wakefulness after sleep onset (WASO) during the intermediate night measure: Wakefulness after sleep onset (WASO) during the high vibration night measure: Number of awakenings during the Control night measure: Number of awakenings during exposure to low vibration measure: Number of awakenings during exposure to intermediate vibration measure: Number of awakenings during exposure to high vibration measure: Sleep onset latency (SOL) during the Control Night measure: Sleep onset latency (SOL) during the low vibration night measure: Sleep onset latency (SOL) during the intermediate vibration night measure: Sleep onset latency (SOL) during the high vibration night measure: Sleep efficiency during the Control night measure: Sleep efficiency during the low vibration night measure: Sleep efficiency during the intermediate vibration night measure: S Sleep efficiency during the high vibration night measure: Sleep depth assessed using the odds ratio product (ORP) during the Control night measure: Sleep depth assessed using the odds ratio product (ORP) during the low vibration night measure: Sleep depth assessed using the odds ratio product (ORP) during the intermediate vibration night measure: Sleep depth assessed using the odds ratio product (ORP) during the high vibration night measure: Maximal change of odds ratio product (ORP) during exposure to railway vibration events measure: Area under the curve of odds ratio product (ORP) during exposure to railway vibration events, calculated using the trapezoid rule measure: N-acetylglucosamine/galactosamine (GlycA) concentration after the Control night measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to low vibration night measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to intermediate vibration measure: N-acetylglucosamine/galactosamine (GlycA) concentration after exposure to high vibration measure: Sialic acid (GlycB) concentration after the Control night measure: Sialic acid (GlycB) concentration after exposure to low vibration measure: Sialic acid (GlycB) concentration after exposure to intermediate vibration measure: Sialic acid (GlycB) concentration after exposure to high vibration measure: Supramolecular phospholipid composite (SPC) concentration after the Control night measure: Supramolecular phospholipid composite (SPC) concentration after exposure to low vibration measure: Supramolecular phospholipid composite (SPC) concentration after exposure to intermediate vibration measure: Supramolecular phospholipid composite (SPC) concentration after exposure to high vibration measure: Ethanol concentration (mmol/L) after the Control night measure: Ethanol concentration (mmol/L) after exposure to low vibration night measure: Ethanol concentration (mmol/L) after exposure to intermediate vibration night measure: Ethanol concentration (mmol/L) after exposure to high vibration night measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to Control night measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to low vibration night measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to intermediate vibration night measure: Trimethylamine-N-oxide concentration (mmol/L) after exposure to high vibration night measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to Control night measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to low vibration night measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to intermediate vibration night measure: 2-Aminobutyric acid concentration (mmol/L) after exposure to high vibration night measure: Alanine concentration (mmol/L) after exposure to Control night measure: Alanine concentration (mmol/L) after exposure to low vibration night measure: Alanine concentration (mmol/L) after exposure to intermediate vibration night measure: Alanine concentration (mmol/L) after exposure to high vibration night measure: Asparagine concentration (mmol/L) after exposure to Control night measure: Asparagine concentration (mmol/L) after exposure to low vibration night measure: Asparagine concentration (mmol/L) after exposure to intermediate vibration night measure: Asparagine concentration (mmol/L) after exposure to high vibration night measure: Creatine concentration (mmol/L) after exposure to Control night measure: Creatine concentration (mmol/L) after exposure to low vibration night measure: Creatine concentration (mmol/L) after exposure to intermediate vibration night measure: Creatine concentration (mmol/L) after exposure to high vibration night measure: Creatinine concentration (mmol/L) after exposure to Control night measure: Creatinine concentration (mmol/L) after exposure to low vibration night measure: Creatinine concentration (mmol/L) after exposure to intermediate vibration night measure: Creatinine concentration (mmol/L) after exposure to high vibration night measure: Glutamic acid concentration (mmol/L) after exposure to Control night measure: Glutamic acid concentration (mmol/L) after exposure to low vibration night measure: Glutamic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Glutamic acid concentration (mmol/L) after exposure to high vibration night measure: Glutamine concentration (mmol/L) after exposure to Control night measure: Glutamine concentration (mmol/L) after exposure to low vibration night measure: Glutamine concentration (mmol/L) after exposure to intermediate vibration night measure: Glutamine concentration (mmol/L) after exposure to high vibration night measure: Glycine concentration (mmol/L) after exposure to Control night measure: Glycine concentration (mmol/L) after exposure to low vibration night measure: Glycine concentration (mmol/L) after exposure to intermediate vibration night measure: Glycine concentration (mmol/L) after exposure to high vibration night measure: Histidine concentration (mmol/L) after exposure to Control night measure: Histidine concentration (mmol/L) after exposure to low vibration night measure: Histidine concentration (mmol/L) after exposure to intermediate vibration night measure: Histidine concentration (mmol/L) after exposure to high vibration night measure: Isoleucine concentration (mmol/L) after exposure to Control night measure: Isoleucine concentration (mmol/L) after exposure to low vibration night measure: Isoleucine concentration (mmol/L) after exposure to intermediate vibration night measure: Isoleucine concentration (mmol/L) after exposure to high vibration night measure: Leucine concentration (mmol/L) after exposure to Control night measure: Leucine concentration (mmol/L) after exposure to low vibration night measure: Leucine concentration (mmol/L) after exposure to intermediate vibration night measure: Leucine concentration (mmol/L) after exposure to high vibration night measure: Lysine concentration (mmol/L) after exposure to Control night measure: Lysine concentration (mmol/L) after exposure to low vibration night measure: Lysine concentration (mmol/L) after exposure to intermediate vibration night measure: Lysine concentration (mmol/L) after exposure to high vibration night measure: Methionine concentration (mmol/L) after exposure to Control night measure: Methionine concentration (mmol/L) after exposure to low vibration night measure: Methionine concentration (mmol/L) after exposure to intermediate vibration night measure: Methionine concentration (mmol/L) after exposure to high vibration night measure: N,N-Dimethylglycine concentration (mmol/L) after Control night measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to low vibration night measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to intermediate vibration night measure: N,N-Dimethylglycine concentration (mmol/L) after exposure to high vibration night measure: Ornithine concentration (mmol/L) after exposure to Control night measure: Ornithine concentration (mmol/L) after exposure to low vibration night measure: Ornithine concentration (mmol/L) after exposure to intermediate vibration night measure: Ornithine concentration (mmol/L) after exposure to high vibration night measure: Phenylalanine concentration (mmol/L) after exposure to Control night measure: Phenylalanine concentration (mmol/L) after exposure to low vibration night measure: Phenylalanine concentration (mmol/L) after exposure to intermediate vibration night measure: Phenylalanine concentration (mmol/L) after exposure to high vibration night measure: Proline concentration (mmol/L) after exposure to Control night measure: Proline concentration (mmol/L) after exposure to low vibration night measure: Proline concentration (mmol/L) after exposure to intermediate vibration night measure: Proline concentration (mmol/L) after exposure to high vibration night measure: Sarcosine concentration (mmol/L) after exposure to Control night measure: Sarcosine concentration (mmol/L) after exposure to low vibration night measure: Sarcosine concentration (mmol/L) after exposure to intermediate vibration night measure: Sarcosine concentration (mmol/L) after exposure to high vibration night measure: Threonine concentration (mmol/L) after exposure to Control night measure: Threonine concentration (mmol/L) after exposure to low vibration night measure: Threonine concentration (mmol/L) after exposure to intermediate vibration night measure: Threonine concentration (mmol/L) after exposure to high vibration night measure: Tyrosine concentration (mmol/L) after exposure toControl night measure: Tyrosine concentration (mmol/L) after exposure to low vibration night measure: Tyrosine concentration (mmol/L) after exposure to intermediate vibration night measure: Tyrosine concentration (mmol/L) after exposure to high vibration night measure: Valine concentration (mmol/L) after Control night measure: Valine concentration (mmol/L) after exposure to low vibration night measure: Valine concentration (mmol/L) after exposure to intermediate vibration night measure: Valine concentration (mmol/L) after exposure to high vibration night measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to Control night measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to low vibration night measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to intermediate vibration night measure: 2-Hydroxybutyric acid concentration (mmol/L) after exposure to high vibration night measure: Acetic acid concentration (mmol/L) after exposure to Control night measure: Acetic acid concentration (mmol/L) after exposure to low vibration night measure: Acetic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Acetic acid concentration (mmol/L) after exposure to high vibration night measure: Citric acid concentration (mmol/L) after Control night measure: Citric acid concentration (mmol/L) after exposure to low vibration night measure: Citric acid concentration (mmol/L) after exposure to intermediate vibration night measure: Citric acid concentration (mmol/L) after exposure to high vibration night measure: Formic acid concentration (mmol/L) after exposure to Control night measure: Formic acid concentration (mmol/L) after exposure to low vibration night measure: Formic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Formic acid concentration (mmol/L) after exposure to high vibration night measure: Lactic acid concentration (mmol/L) after exposure to Control night measure: Lactic acid concentration (mmol/L) after exposure to low vibration night measure: Lactic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Lactic acid concentration (mmol/L) after exposure to high vibration night measure: Succinic acid concentration (mmol/L) after exposure to Control night measure: Succinic acid concentration (mmol/L) after exposure to low vibration night measure: Succinic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Succinic acid concentration (mmol/L) after exposure to high vibration night measure: Choline concentration (mmol/L) after exposure to Control night measure: Choline concentration (mmol/L) after exposure to low vibration night measure: Choline concentration (mmol/L) after exposure to intermediate vibration night measure: Choline concentration (mmol/L) after exposure to high vibration night measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to Control night measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to low vibration night measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to intermediate vibration night measure: 2-Oxoglutaric acid concentration (mmol/L) after exposure to high vibration night measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to Control night measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to low vibration night measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to intermediate vibration night measure: 3-Hydroxybutyric acid concentration (mmol/L) after exposure to high vibration night measure: Acetoacetic acid concentration (mmol/L) after exposure to Control night measure: Acetoacetic acid concentration (mmol/L) after exposure to low vibration night measure: Acetoacetic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Acetoacetic acid concentration (mmol/L) after exposure to high vibration night measure: Acetone concentration (mmol/L) after exposure to Control night measure: Acetone concentration (mmol/L) after exposure to low vibration night measure: Acetone concentration (mmol/L) after exposure to intermediate vibration night measure: Acetone concentration (mmol/L) after exposure to high vibration night measure: Pyruvic acid concentration (mmol/L) after exposure to Control night measure: Pyruvic acid concentration (mmol/L) after exposure to low vibration night measure: Pyruvic acid concentration (mmol/L) after exposure to intermediate vibration night measure: Pyruvic acid concentration (mmol/L) after exposure to high vibration night measure: D-Galactose concentration (mmol/L) after exposure to Control night measure: D-Galactose concentration (mmol/L) after exposure to low vibration night measure: D-Galactose concentration (mmol/L) after exposure to intermediate vibration night measure: D-Galactose concentration (mmol/L) after exposure to high vibration night measure: Glucose concentration (mmol/L) after exposure to Control night measure: Glucose concentration (mmol/L) after exposure to low vibration night measure: Glucose concentration (mmol/L) after exposure to intermediate vibration night measure: Glucose concentration (mmol/L) after exposure to high vibration night measure: Glycerol concentration (mmol/L) after exposure to Control night measure: Glycerol concentration (mmol/L) after exposure to low vibration night measure: Glycerol concentration (mmol/L) after exposure to intermediate vibration night measure: Glycerol concentration (mmol/L) after exposure to high vibration night measure: Dimethylsulfone concentration (mmol/L) after exposure to Control night measure: Dimethylsulfone concentration (mmol/L) after exposure to low vibration night measure: Dimethylsulfone concentration (mmol/L) after exposure to intermediate vibration night measure: Dimethylsulfone concentration (mmol/L) after exposure to high vibration night measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the control night measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the low vibration night measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the intermediate vibration night measure: Response to an oral glucose bolus, calculated as area under curve for glucose, in the morning after the high vibration night measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the low vibration night measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the intermediate vibration night measure: Response to an oral glucose load calculated as area under curve for insulin, in the morning after the high vibration night measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the control night measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the low vibration night measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the intermediate vibration night measure: Early response to an oral glucose load calculated as area under curve for insulin, in the morning after the high vibration night measure: Glucose tolerance in the morning after exposure to low vibration, assessed as glucose concentration 120 minutes after a glucose bolus measure: Glucose tolerance in the morning after exposure to intermediate vibration, assessed as glucose concentration 120 minutes after a glucose bolus measure: Glucose tolerance in the morning after exposure to high vibration, assessed as glucose concentration 120 minutes after a glucose bolus measure: Glucose tolerance in the morning after Control night, assessed as glucose concentration 120 minutes after a glucose bolus measure: Stumvoll Insulin sensitivity Index in the morning after control measure: Stumvoll Insulin sensitivity Index in the morning after exposure to low vibration measure: Stumvoll Insulin sensitivity Index in the morning after exposure to intermediate vibration measure: Stumvoll Insulin sensitivity Index in the morning after exposure to high vibration measure: Matsuda insulin sensitivity index in the morning after control exposure measure: Matsuda insulin sensitivity index in the morning after exposure to low vibration measure: Matsuda insulin sensitivity index in the morning after exposure to intermediate vibration measure: Matsuda insulin sensitivity index in the morning after exposure to high vibration measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to control measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to low vibration measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to intermediate vibration measure: Evening subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to high vibration measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to control measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to low vibration measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to intermediate vibration measure: Morning subjective sleepiness, assessed using the Karolinska Sleepiness Scale after exposure to high vibration measure: Self-reported sleep disturbance by vibration after control exposure measure: Self-reported sleep disturbance by vibration after exposure to low vibration measure: Self-reported sleep disturbance by vibration after exposure to intermediate vibration measure: Self-reported sleep disturbance by vibration after exposure to high vibration measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after control exposure measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration measure: Morning positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after control exposure measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration measure: Morning negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to control measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration measure: Evening negative affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to control measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to low vibration measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to intermediate vibration measure: Evening positive affect, assessed using the Positive and Negative Affect Schedule (PANAS) after exposure to high vibration measure: Event-related cardiovascular activation in response to control measure: Event-related cardiovascular activation in response to low vibration measure: Event-related cardiovascular activation in response to intermediate vibration measure: Event-related cardiovascular activation in response to high vibration measure: Evening neurobehavioural speed measure: Evening neurobehavioural accuracy sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: University of Gothenburg status: RECRUITING city: Gothenburg state: Västra Götaland zip: 42650 country: Sweden name: Michael G Smith, PhD role: CONTACT phone: +46317862843 email: [email protected] lat: 57.70716 lon: 11.96679 hasResults: False
|
<|newrecord|> nctId: NCT06260241 id: ShaikhZayedH briefTitle: Gain in Stretched Penile Length After Phalloplasty With & Without Penile Traction in Children. overallStatus: RECRUITING date: 2023-01-01 date: 2025-01-01 date: 2025-01-01 date: 2024-02-15 date: 2024-02-15 name: Shaikh Zayed Hospital, Lahore class: OTHER briefSummary: The goal of this Randomized Controlled Trial is to assess the gain in stretched penile length after phalloplasty with \& without penile traction in children of age group 4 to 13 years presenting in hospital with the complaint of concealed penis.
|
The main question\[s\] it aims to answer is:
|
• Gain in stretched penile length after phalloplasty with and without penile traction in children. conditions: Concealed Penis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Control Trial primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 70 type: ESTIMATED name: Traction Dressing name: Without Traction Dressing measure: The gain in stretched penile length (SPL) sex: MALE minimumAge: 4 Years maximumAge: 13 Years stdAges: CHILD facility: Sheikh Zayed Hospital status: RECRUITING city: Lahore state: Punjab country: Pakistan name: ADEEL AHMED, MBBS MS role: CONTACT phone: 00923491467739 email: [email protected] lat: 31.558 lon: 74.35071 hasResults: False
|
<|newrecord|> nctId: NCT06260228 id: STUDY02002270 briefTitle: HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's) acronym: HOBSCOTCH-PD overallStatus: RECRUITING date: 2024-01-05 date: 2024-08-01 date: 2024-11-30 date: 2024-02-15 date: 2024-02-15 name: Dartmouth-Hitchcock Medical Center class: OTHER briefSummary: The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Parkinson's Disease (PD)
|
The main questions it aims to answer are:
|
1. Can the current HOBSCOTCH program be adapted for people with PD?
|
2. Will people with PD experience improved quality of life similar to that found in people with epilepsy after participating in the HOBSCOTCH program?
|
Participants will be asked to:
|
* attend nine, one-hour virtual (online and/or by telephone) HOBSCOTCH-PD sessions with a one-on-one certified HOBSCOTCH-PD coach
|
* complete a brief clinical questionnaire about their diagnosis of PD
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.